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Lentiviral restriction factors (RFs) are cellular proteins potently capable of blocking virus 
replication in vitro and delaying disease progression in vivo. Currently, five RFs (APOBEC3G, 
TRIM5α, Tetherin, SAMHD1, and Schlafen 11) are considered part of the intrinsic immune 
response to viral infection for their ability to block virus replication prior to activation of the 
innate immune system. Although RFs are constitutively expressed, it is unknown whether basal 
and early induction levels of these RFs are capable of limiting virus dissemination following 
mucosal challenge. We hypothesize that higher basal RF levels can exert a protective effect by 
delaying systemic infection. Real-time PCR analysis was conducted to analyze basal and post-
exposure RF expression in the blood, lymph nodes and duodenum. Eight Indian-origin rhesus 
macaques received repetitive low dose rectal exposures of SIV/DeltaB670: 3 macaques became 
infected after 2 challenges (susceptible), 2 became infected after 3 challenges (intermediate), 
while two became infected after 6 challenges (resistant). One animal remained persistently 
uninfected despite 7 challenges (elite controller). Analysis of basal RF and Mx1 expression in 
the blood revealed animals resistant to infection had significantly higher TRIM5α and Mx1 
expression than susceptible animals. Longitudinal analysis of RF and Mx1 expression in the 
blood revealed no RF induction in the resistant group, while the susceptible and intermediate 
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groups experienced a 2 to 7-fold induction after virus appearance in the blood. Despite the lack 
of RF induction in the elite controller, a transient induction of Mx1 was evident after 2 of the 7 
challenges, which may have provided further protection. Examination of RF induction in the gut 
revealed a similar pattern with expression mirroring that seen in the blood. Our results suggest 
that RFs are coordinately expressed in the blood and gut in response to infection and that levels 
remain unchanged, despite repeated exposure, until the animals become viremic. As such, 
induction of these RFs after virus exposure appears to be insufficient in containing virus 
dissemination. These results further suggest that basal RF levels in the blood may be used as a 
predictor for susceptibility to infection in macaques and possibly humans.  
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1.0  INTRODUCTION 
The acquired immunodeficiency syndrome (AIDS) epidemic has devastated the lives of millions of 
people worldwide with no reachable cure in sight. Despite the advent of antiretroviral therapy to limit 
virus replication and disease pathogenesis, the disease is still incurable. The human immunodeficiency 
virus (HIV), the causative agent of AIDS, was discovered more 30 years ago and found to primarily 
spread among individuals by sexual transmission [1]. While many sexually transmitted diseases have 
garnered notable attention from the medical community, HIV has been in the limelight due to the virus’s 
inherent ability to infect the immune cells responsible for host defense and evading the subsequent 
immune response through mutational escape [2]. HIV is characterized with an extremely error prone 
reverse transcriptase (RT). The remarkable ability of HIV to constantly mutate allows it to evade 
neutralizing antibodies and the cytotoxic T cell response therefore rendering the host incapable of fully 
attenuating the virus [3]. Not only does its high error-prone RT devastate the mounted host immune 
response, but HIV, and retroviruses in general, can permanently integrate their genome into the host 
making them one of the most successful parasites in nature [4].  
1.1 HIV VIROLOGY 
HIV is a member of the retroviridae family and carries two (+) ssRNA strands encoding three essential 
genes gag (Glycoproteins), pol (Polymerases), and env (Envelope), and their mRNAs are further spliced 
to encode proteins necessary for the structure of the virus. In addition to these essential genes are 
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accessory genes (Vif, Vpu, Vpr, Nef) generally known to be dispensable for the survival of the virus in 
vitro but necessary for its pathogenesis in vivo [5,6]. HIV has a spherical morphology with a lipid bilayer 
membrane derived from the host cell and encapsidates a cone-shaped core called the nucelocapsid [7]. 
Within the nucleocapsid are the two strands of genomic RNA and proteins necessary for virus replication: 
protease, RT, integrase, Vpu, Nef, Vif, and Vpr. Tat and Rev are known as regulatory genes for their 
ability to control transcription and RNA export, respectively [8]. HIV’s glycoprotein (gp120) mediates 
binding to the host cell through the CD4 receptor and the CCR5/CXCR4 coreceptors (Figure 1) [7]. 
Thereafter, the viral and host membranes fuse and the viral core is released into the cytoplasm. At this 
point, uncoating occurs and the viral RNA undergoes reverse transcription and the resulting double 
stranded cDNA can be transported into the nucleus for integration into the host genome. The integrated 
cDNA serves as the genetic template for the viral proteins to be encapsidated into new virions and also 
serves as the viral genomic RNA. Assembly and packaging of new virions occurs at the plasma 
membrane and newly made virions bud from the host lipid bilayer, acquiring a portion of the bilayer as a 
coat for the virus. 
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Figure 1. Schematic of the HIV replication cycle in a host cell. 
Numbered are the different steps in the life cycle: 1,2) fusion and entry 3) reverse transcription 4) genome 
integration 5) translation 6) assembly 7) budding. Figure adapted from [9] with permission.  
 
1.2 ORIGIN OF HIV 
While it is not fully clear how HIV emerged into the human population, scientists attempted to approach 
this question by examining the genetic background of HIV. Two forms of HIV exist in the human 
population: HIV-1 and HIV-2. HIV-1 is the primary virus causing the global HIV epidemic while HIV-2 
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is less pathogenic and mostly localized to West Africa [10]. By analyzing the genetic sequence of HIV, 
scientists traced the origin of HIV-1 to a simian form of this virus found in chimpanzees (cpz). 
Specifically, HIV-1 group M was found to be the result of a chimpanzee to man zoonotic transmission of 
simian immunodeficiency virus (SIVcpz), a lentivirus commonly found in chimpanzees with high genetic 
similarity to HIV-1 [10]. Group M is the HIV-1 group that gave rise to the AIDS pandemic and is found 
throughout the world [10]. HIV-2, on the other hand, was derived from sooty mangabeys and is more 
genetically similar to SIV strains than HIV-1 [10]. Genetic analysis between HIV and SIV viruses shows 
high homology with differences in the presence/absence of accessory genes (Figure 2).  
 
 
 
 
Figure 2. Schematic of the SIV and HIV genomes. 
Accessory genes are shown in yellow. Figure adapted from [3] with permission.  
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1.3 SIV DIVERSITY 
Both HIV-1 and HIV-2 were derived from a zoonotic transmission from an SIV isolate found in 
chimpanzees and sooty mangabeys, respectively [11]. Although SIV is genetically distinct from HIV-1 
and HIV-2, it has allowed scientists to better explain the nature of HIV-1 pathogenesis by analyzing SIV 
pathogenesis in the nonhuman primates that harbor SIV. More than 40 different lentiviruses are naturally 
found in old world monkeys in sub-Saharan Africa [10]. Some of these lentiviruses underwent cross-
species transmission to humans and great apes leading to the rise SIVcpz, SIVgor, HIV-1, HIV-2, and 
SIVmac. The most commonly studied SIV strains are 1) SIVcpz, found in chimpanzees 2) SIVsm, found 
in sooty mangabeys 3) SIVgor, found in gorillas 4) SIVagm, found in African green monkeys 5) SIVptm, 
found in pig-tailed macaques, and 6) SIVmac, found in rhesus macaques. Of particular interest is 
SIVmac, which was inadvertently transmitted from sooty mangabeys infected with SIVsm and became 
highly adapted in macaques after several passages of the original SIVsm virus in rhesus macaques [12].  
SIVmac strains are the most commonly studied strains in SIV research for their ability to cause similar 
infection and disease pathogenesis as seen with HIV-1 infected humans. 
1.4 HIV/SIV PATHOGENESIS 
 The cellular target of HIV/SIV is the primary reason no potent cure has been discovered. After HIV/SIV 
pass the mucosal epithelial layer, they specifically target and replicate in CD4+ T cells, the working 
horse of the host immune system. CD4+ T cells delegate tasks to other immune cells and are a stimulant 
of the adaptive immune system [13]. Both HIV and SIV infections are categorized by three phases: acute 
infection phase, asymptomatic phase, and the immunodeficiency onset phase (AIDs) [14]. The first 
phase is characterized by virus dissemination to lymphoid tissue and rapid virus replication [15]. The 
second phase involves low-level virus replication, an attribute of the lentivirus subfamily of retroviruses, 
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which can take several years. The third and final stage of infection is characterized by a compromised 
immune system as a result of significant gut CD4+ T cell depletion, immune activation, and microbial 
translocation [16]. Within 7-10 years, an HIV-infected individual begins the chronic stage of virus 
replication, immunodeficiency, and opportunistic infections [17]. At this point, the host’s immune 
system has been severely compromised. Consequently, the acute phase of infection is the most critical 
phase for effective inhibition of further pathogenesis to the host. 
 The unique ability of RT to cause mutations in the viral genome and HIV’s ability to 
integrate into the genome of host immune cells has contributed to the success of this virus in creating an 
incurable epidemic thus far. Overall, several factors contribute to the lack of effective drugs/vaccines: 1) 
HIV infects the immune cells (CD4+ T) that are responsible for defending the host; 2) HIV RT introduces 
numerous mutations in the viral genome; 3) the constantly evolving genetic sequence of HIV causes 
evasion from neutralizing antibodies and the cytotoxic T lymphocyte (CTL) response; 4) HIV becomes 
integrated into the host genome and capable of virus production indefinitely; and 5) HIV establishes 
reservoirs of latent virus in several tissues that cannot be easily accessed by drugs/immune system. 
1.5 RHESUS MACAQUE MODEL 
 To understand the in vivo nature of the host immune response to HIV and to develop methods to intervene 
with virus replication, it was imperative to design an animal model that mimicked the HIV scenario seen 
with humans. Understanding HIV-host interactions at the site of transmission is imperative to design 
preventative drugs/vaccines that can effectively eliminate HIV in the mucosa (rectum, vaginal and 
intestinal tract). Due to ethical and practical reasons, it is impossible to sample humans immediately after 
virus transmission. However, with the development of SIV-infected rhesus macaque models, it is now 
possible for scientists to understand the course of virus dissemination from the genital tract to the 
periphery. SIV-infected rhesus macaques are the most successful model to study HIV transmission not 
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only for the ability to control tissue sampling and route/dose of exposure, but also because SIV is the 
most closely related virus to HIV both with regards to structure and host pathogenic effect [18,19]. Even 
more important are the similarities in the anatomy, physiology, and immunology of the reproductive tract 
of rhesus macaques and humans [20]. Essentially, the rhesus macaque model enables scientists to analyze 
early and late host immune responses to virus in many different tissue compartments. 
1.6 SEXUAL TRANSMISSION 
 Sexual transmission of HIV is the world-leading cause of the AIDS epidemic. Despite the significant 
amount of effort and resources devoted to study mechanisms of HIV transmission, millions of humans 
become newly infected every year due to the lack of potent therapeutics that can eliminate the virus at the 
site of transmission. After sexual transmission, HIV can cross the female cervicovaginal tract by: 1) 
epithelial breaches; 2) uptake by dendritic cells (DCs); 3) transcytosis (Figure 3) [20]. Within hours, a 
founder population of infected resting CD4+ T cells is established. Local expansion of the founder 
population through the recruitment of CD4+ T cells occurs within days from virus entry and is necessary 
to allow for sufficient virus production and peripheral dissemination [20]. Within one week, the virus can 
disseminate to the draining lymph nodes and reach the peripheral lymphoid tissue and blood. At that 
point, the virus has taken hold of the host immune system and has established a lymphatic tissue 
reservoir. These reservoirs serve as virus-producing compartments, whereby the viral genome becomes 
integrated into the host genome and capable of producing virus indefinitely.  
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Figure 3. Mucosal transmission of HIV/SIV. 
Virus can cross the epithelial barrier by: 1a) transcytosis; 1b) uptake by DCs; 1c) epithelial breaches. 
Virus then establishes a founder population and expands locally. Thereafter, virus establishes a lymphoid 
tissue reservoir and is disseminated systemically. To the right, is a timeline for each step during viral 
transmission and dissemination. Large yellow errors indicate possible time points when the restriction 
factors (RFs) may have a potent impact on virus replication and dissemination. Figure designed using 
www.proteinlounge.com and content was obtained from [20]. 
 
 
 Studies have shown that the optimal time to prevent virus dissemination and further 
damage to the host is during the first week of exposure, when the virus is most vulnerable [21]. After SIV 
enters a host, DNA is not detectable in the blood or lymphatic tissue during the first seven days and this 
time period is regarded as the eclipse period. During these 7-10 days, the virus is attempting to establish a 
local infection and this timeframe is therefore regarded as the “window of opportunity” for potent 
intervention of virus replication and further damage to the host [21].  
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1.7 SIV RECTAL CHALLENGES 
 Sexual transmission of HIV can occur through the vaginal, rectal, or oral route [19,22]. While the 
majority of HIV transmissions occur through the vaginal route and thus necessitate female macaques for 
these studies, female macaques are often saved for breeding purposes. Consequently, the majority of SIV 
studies have focused on utilizing the rectal route of exposure to study HIV/SIV pathogenesis.  
 While many SIV animal studies have examined SIV transmission by the intravenous 
route, a mucosal model of SIV exposure is more relevant to studying HIV transmission in humans. This 
will be extremely beneficial in the long run in the development of therapeutics and drugs to curb HIV 
transmission. Several studies have delineated the pathway of SIV transmission from the rectum to the 
peripheral organs and blood. These studies have examined rectal infection through various methods of 
exposure. Among the possible routes of experimental SIV rectal exposure in macaques is: 1) a single high 
dose challenge; and 2) a repetitive, low dose challenge. Repetitive, low dose rectal SIV challenges have 
been shown to recapitulate HIV-1 mucosal infection in humans [23]. Similarly, studies show that this type 
of challenge may enable the host immune system to curb the virus during the early stages of replication 
due to the low number transmitted variants that pass the rectal barrier [24]. In my case, low-dose 
challenges can enable us to monitor the innate immune response to examine, in real-time, the effect of 
specific proteins before and after systemic infection. Not all challenges with repetitive low-doses of virus 
result in 100% infection and can thus be exploited by scientists to understand the reasons causing this 
effect. More importantly, repetitive, low dose rectal challenges may initiate a localized mucosal immune 
response that can block further virus replication and dissemination [25]. 
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1.8 INNATE IMMUNE RESPONSE 
 For years, scientists have struggled to understand virus-host interactions of HIV by examining the virus’s 
behavior in different tissue compartments. Only recently have researchers begun to focus closely on the 
mucosal portal of entry for HIV and the potential of innate immune responses in limiting viral 
dissemination from the vaginal tract/rectum. In order to avoid the deleterious effects of virus replication, 
it is imperative to halt the virus from disseminating beyond the mucosa. Several factors can contribute to 
blocking virus replication and include both intrinsic host factors and man-made interventions such as 
microbicides, antiretroviral therapy, and vaccines [21]. However, all these factors culminate in the 
engagement of the host innate immune response.  
 After a foreign particle enters the host, two forms of defense are capable of eliminating 
that particle: the innate immune response and the adaptive immune response.  The innate immune system 
is considered the first line of defense against viral infection [26]. It is specifically characterized as an 
immediate immune response to any foreign antigen through the recruitment and activation of immune 
cells capable of killing the pathogen. These innate immune cells include macrophages, natural killer cells 
(NK), complement, and DCs, and are conveniently located at the portal of entry for HIV [21]. An 
extremely notable feature of the innate immune response is its ability to react within minutes to hours 
from stimulation by a foreign antigen.  
 Although many cytokines are involved in a mounted innate immune response, of 
particular importance is type I interferons. Interferons are crucial in the defense against viral infections 
[27]. With respect to HIV/SIV infection, the host’s innate immune system responds to virus infection by 
upregulation of type I interferons that, in turn, induce a myriad of interferon-stimulated genes (ISGs) to 
create an “antiviral” environment in nearby cells (Figure 4) [28,29]. Well-known ISGs effective against a 
range of viruses include the Mx proteins. These proteins are considered among the most potent antiviral 
genes and are only induced by type I interferons. They are found as oligomers within the cell and bind to 
critical viral components to degrade them [27]. Studies have shown that the lack of Mx proteins in mice 
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contribute to decreased resistance to viral infection [27]. However, among the ISGs that have garnered 
significant attention for their potent ability to inhibit HIV/SIV replication are a group of cellular proteins 
termed restriction factors (RFs). These RFs, (TRIM5α, APOBEC3G, tetherin, SAMHD1, and schlafen 
11), are both constitutively expressed and inducible by type I interferons, thereby making them members 
of the ISG family that defines innate immunity [28,30,31,32,33,34]. Their strength is further validated in 
their ability to restrict virus as single genes without the aid of cellular cofactors [30].  
 
 
 
 
 
Figure 4. Virus activation of type I interferons. 
After virus entry and detection in a cell by TLR3, a signaling cascade is initiated to allow IFNβ 
transcription and secretion. Secreted IFNβ binds to the IFNAR receptor in nearby cells and initiates 
another signaling cascade to stimulate transcription of interferon-stimulated genes (ISGs) such as Mx 
proteins. Virus can also directly activate IFNα and IFNβ transcription, which can then act in an autocrine 
fashion to further amplify the production of ISGs needed for defense against the pathogen. Figure adapted 
from [35] with permission. 
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1.9 RESTRICTION FACTORS (RFS) 
Lentiviral RFs are specifically classified as part of the intracellular intrinsic immune response, in that 
they cause early resistance to virus infection without previous signaling/virus infection and are capable of 
acting autonomously without the aid of cellular cofactors [3,30,36,37,38,39,40,41,42]. RFs act as a 
frontline defense system due to their constitutive expression and capability of counteracting retroviruses 
before activation of the innate and adaptive immune system [43,44]. In fact, one study suggested that host 
factors may dominantly contribute to virus inhibition prior to the onset of immune responses and may be 
critical in establishing the early and post-acute viral replication patterns in vivo [18]. In other words, RFs 
may delay productive infection and dissemination. By definition, lentiviral RFs are dominantly-acting, 
germline-encoded cellular proteins that are constitutively expressed and capable of being induced by IFN 
[30]. They are species-specific and display signs of positive selection indicating coevolution between the 
virus and the RF [30]. In general, these RFs are potent cellular proteins but are inactive against the 
wildtype virus that is present in the natural host. This phenomenon is due to the presence of virally-
encoded antagonists that counteract the restrictive function of these RFs through the ubiquitin-proteasome 
pathway. RFs have been in the spotlight of lentiviral research because of a discovery claiming the 
inhibition of HIV replication in rhesus macaque cells due to the rhesus RF, TRIM5α. In essence, rhesus 
macaque TRIM5α is capable of creating an outright block of HIV-1 replication in rhesus macaque cells 
but not in human cells; thus explaining the current inability of creating an HIV-rhesus macaque model 
[45]. This groundbreaking discovery proved that RFs alone have the power to completely block HIV 
entry in these cells. Such results spurred numerous studies to identify other RFs that can mimic the 
restrictive ability of TRIM5α.  
 Over the years, more lentiviral RFs have been discovered. Each of the currently known 
RFs has a different inhibitory target within the viral life cycle: APOBEC3G, TRIM5α, and SAMHD1 
pose an early (post-entry) block on the first stages of reverse transcription while SCHL11 and tetherin 
inhibit translation and virion budding, respectively (Figure 5) [30,31,39,45,46,47]. Together, these RFs 
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act as independent barriers the virus must overcome to productively infect other cells. In addition to their 
positive selection and coevolution with HIV/SIV, the synergistic function of these RFs makes them 
powerful antagonists of lentiviral cross-species transmission [10,12,30,40].  
 
 
 
 
Figure 5. Schematic of the direct role of RFs in the host cell. 
Shown are the RFs in red: TRIM5α, SAMHD1 and A3G pose an early block on reverse transcription and 
integration. Tetherin poses a late effect by blocking virion budding. This figure does not show the 
function of Schlafen 11. Corresponding antagonists for SAMHD1 (Vpx), A3G (Vif), and tetherin (Env, 
Nef, Vpu) are shown in green. Each antagonist recruits cellular proteins involved with the endocytosis or 
direct ubiqutination of the RF. Lower left box gives a detailed view of A3G hypermutation in the viral 
cDNA. Figure adapted from [39] with permission. 
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 Both humans and rhesus macaques express all five RFs and they are fully ineffective in 
their natural hosts due to the virally-encoded antagonists. However, rhesus RFs are capable of strongly 
inhibiting HIV replication but are weakly capable of blocking SIV replication. The fact that lentiviruses 
have evolved specific proteins to combat these RFs reinforces the inherent ability of these RFs in potently 
blocking virus replication. In other words, HIV/SIV cannot simply escape RF restriction by mutating, but 
it has to specifically encode proteins within its genome to combat them individually [3]. As previously 
discussed, Ashley Haase proposed that two windows of opportunity exist for successful intervention 
against HIV replication and disease pathogenesis. The first window is during the first seven days after 
exposure and before systemic infection; and the second is before lymphatic dissemination. Since these 
RFs are constitutively expressed, I believe they may have a potent inhibitory effect during these two 
“windows of opportunity,” before virus dissemination to the periphery. My study will specifically analyze 
this aspect. 
1.9.1 APOBEC3G  
 Apolipoprotein B mRNA-editing, catalytic polypeptide-like 3G (A3G) is a member of a family of 
proteins that function as cytidine deaminases [48]. These proteins serve to protect the host from genomic 
instability caused by endogenous retroelements, especially in the germline [6,48,49]. A3G consists of an 
N-terminal deaminase inactive domain and a C-terminal deaminase active domain. The C-terminal 
domain functions as the cytosine deaminase while the N-terminal domain aids in A3G packaging into the 
virion and viral RNA binding through the nucleocapsid [30]. A3G is the only RF packaged within virions 
for immediate action post virus entry during reverse transcription. The restrictive function of A3G is 
manifested in both deaminse-dependent and deaminase-independent pathways (Figure 6). After 
packaging into virions from the producer cell, A3G functions in the target cell as: 1) a cytidine 
deaminase causing G to A hypermutations in the (-) strand of viral cDNA further inhibiting cDNA 
integration into the host genome; and 2) an inhibitor of the accumulation of HIV-1 reverse transcripts 
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(cDNA) [50,51,52]. Post viral entry into the cell, A3G begins deaminating cytosines to uracils during 
reverse transcription, causing deamination in up to 10% of the cytosines [30]. A3G, however, has a 
particular preference for the underlined cytosine 5’-CCCA [51]. These deaminations cause G to A 
hypermutations that can create frequent stop codons and compromise the integrity of the viral genome as 
a result of the introduction of an unnatural base into the DNA sequence [30,53]. In general, 
hypermutations have been associated with slower disease progression [54]. As a consequence of the 
aberrant DNA ends caused by hypermutations, the viral cDNA’s ability to integrate into the host genome 
is compromised [55]. As part of its second function, A3G inhibits the translocation of reverse 
transcriptase during reverse transcription thereby hampering cDNA elongation and contributing to a lower 
viral cDNA level [50]. Specifically, A3G decreases tRNA specificity and processivity of translation by 
deaminating cytosines in the primer-binding site [56,57].  
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Figure 6. A3G's diverse inhibitory effects on HIV-1. 
A3G is packaged within the budding virion and blocks virus replication in the target cell by: 1) 
deaminase-independent activity; 2) deaminase-dependent activity and 3) blocking integration as a result 
of aberrant ends. Figure adapted from [5] with permission. 
 
 
 Several studies have shown the inhibitory effect of A3G on HIV-1 and its restrictive 
ability on HIV-2, murine leukemia virus (MLV), and foamy viruses [48,58]. While A3G is effective in its 
restriction, HIV/SIV has evolved a protein, Vif (virion infectivity factor), that can block A3G’s restrictive 
ability in three ways. First, Vif recruits the E3 ubiquitin ligase complex to ubiquitinate A3G and allow its 
proteasomal degradation prior to packaging in newly budding virions [55,59]. Second, Vif inhibits A3G 
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encapsidation into virions by competing with A3G for viral RNA binding by forming a complex with 
A3G [52,53,59]. Third, HIV-1 Vif binds to huA3G mRNA and inhibits its translation [60]. Vif is very 
efficient in its antagonistic ability regardless of the level of A3G present in a cell [30]. However, A3G 
neutralization by Vif is not absolute and studies show IFNα induction of A3G allows evasion from Vif’s 
neutralizing effect [49,51,61].  
 Human and rhesus A3G are 75% similar but are species-specific [53]. A3G can have 
variable inhibitory effects in species depending on the genetic interaction between A3G and Vif [53,62]. 
For example, humans encode an L128 in A3G that allows A3G to be antagonized by HIV Vif while 
African green monkey A3G has an aspartic acid in that location that allows its specific inhibition by 
SIVagm Vif [30]. Residues D128 and D130 in A3G are critical residues for Vif binding [56]. A3G 
proteins in humans, macaques, African green monkeys, and chimpanzees can be combated by the natural 
lentivirus infecting that species (ex: SIVmac Vif inhibits rhesus (rh) A3G), but are unaffected by the Vif 
in other virus strains (ex: rhA3G unaffected by HIV-1 Vif) [49]. Studies have shown coevolution between 
A3G and Vif and it is believed that Vif’s ability to counteract the A3G of new hosts has played a role in 
the zoonotic transmission of SIV to humans [30,63].   
1.9.2 TRIM5α  
 TRIM5α is a member of the tripartite motif family known for their ability to self-associate and 
multimerize [64]. All TRIM proteins contain a RING, B-Box, and coiled coil domain [65]. Specifically, 
the RING domain functions as an E3 ubiquitin ligase, while the B-box and coiled coil are both involved 
in self association [64]. TRIM5α is an isoform of TRIM5 that is distinguishable from other TRIM 
proteins by the presence of the C-terminal B30.2/PRYSPRY domain. This domain is the most crucial 
component of the TRIM5α protein because it acts as the determinant for viral capsid binding and efficient 
restriction [65,66]. Its inhibitory effect is manifested both post-viral entry, pre-integration of the viral 
genome, and late during the viral life cycle. In other words, TRIM5α appears to have several routes of 
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restriction: 1) it binds to the capsid and mediates fragmentation, thereby inhibiting reverse transcription; 
2) it blocks viral cDNA entry into the nucleus for integration; 3) it degrades Gag polyproteins during the 
late phase of replication; and 4) it triggers an alarm by activating the NfκB pathway to alert neighboring 
cells of an ensuing infection [67,68,69,70]. Therefore, TRIM5α activity is coupled with stimulation of the 
innate immune response.  
 Upon virus entry, TRIM5α binds to the capsid through the SPRY domain and allows 
multimerization in the form of a hexameric protein lattice [71]. Thereafter, the autocatalytic function of 
TRIM5α allows it to ubiquitinate itself, which consequently allows for degradation by the proteasome 
(Figure 7). The movement of the capsid-bound TRIM5α to the proteasome disrupts the capsid, causing 
fragmentation [72,73].  
 Although several studies elucidated the current restrictive function of TRIM5α, the 
natural function of TRIM5α in cells was not clear. However, after the discovery of TRIM5α’s capacity to 
activate the Nfκb pathway and promote cytokine production, it is now clear that it acts as a pattern 
recognition receptor that is specific for the retrovirus capsid [68]. 
 
 
 
 
Figure 7. TRIM5α-mediated uncoating of the viral capsid. 
TRIM5α binds to the capsid after viral entry and multimerizes on the capsid surface forming a hexamer 
lattice. TRIM5α’s autoubiquitinating activity facilitates disassembly of the viral core by moving toward 
the proteasome. Figure adapted from [74] with permission. 
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 Again, due to the species-specific nature of RFs, TRIM5α is generally ineffective against 
the retroviruses naturally found in a host species but is potent against retroviruses in other species [30]. 
Although human and rhesus TRIM5α are 87% similar, rhTRIM5α can block HIV-1 replication but not 
SIVmac, while huTRIM5α can potently block N-MLV but not HIV-1 [75,76]. The level of inhibition on 
N-MLV replication induced by huTRIM5α is similar to the level induced against HIV-1 by rhTRIM5α 
[66]. Differences in huTRIM5α’s ability to potently combat N-MLV and not HIV-1 is due to the nature of 
the restriction site and the shape of the capsid [74,77]. The specific residues in the SPRY domain 
contribute to these differences among the two retroviruses [71]. Studies have revealed the importance of 
an amino acid mutation (R332P) in the huTRIM5α SPRY domain that can lead to efficient HIV-1 
restriction [66]. Both rhesus macaque and African green monkey TRIM5α express the proline residue and 
therefore both are effective inhibitors of HIV-1 [66].  
Rhesus TRIM5α is highly polymorphic in the C-terminal B30.2/PRYSPRY domain with 
a specific polymorphism at amino acids 339-341 highly linked to susceptibility to infection and disease 
progression induced by specific SIV isolates [12]. These polymorphisms reside in the regions that bind to 
the SIV capsid and affect the strength of the TRIM5α-capsid interaction and therefore restriction 
[78,79,80]. Three different allelic forms in the 339-341 region of TRIM5 exist: TRIM5TFP, TRIM5Q, and 
TRIMCYPA. TRIMCYPA contains a complete substitution of the B30.2/PRYSPRY domain with the 
cyclophilin A gene as a result of retrotransposition and is restrictive against retroviruses whose capsids 
typically bind cyclophilin A such as HIV-1 and FIV [30,68,81,82].  
 These TRIM5α alleles may exhibit various restriction capabilities depending on the type 
of virus, route of exposure, viral dose, and prior vaccination [83]. Transmission and acquisition of SIV 
can be severely impaired if the recipient host expresses the restrictive TRIM5 alleles (TFP or CypA) and 
the effect may be more pronounced with low-dose challenges because it may contribute to the genetic 
bottleneck [12,84]. In fact, one group has shown that the restrictive TRIM5 alleles are capable of 
affecting mucosal acquisition of SIVsmE660 even without prior vaccination [85]. In other words, these 
alleles act as a standalone barrier that are potent in crippling the early stage of transmission. Macaques 
 19 
with restrictive alleles show attenuated replication after SIV exposure by the IV route whereas those 
exposed mucosally show an outright block to SIVsmE660 [86]. Similarly, studies show that animals 
homozygous for the TFP allele are more resistant to SIV infection and display lower peak VLs and slower 
disease progression (lower viral set-point and less CD4+ T cell depletion) [12,79]. Thus, animals with 
restrictive alleles display significantly higher survival rates versus animals bearing at least one permissive 
allele [79]. In fact, these polymorphisms account for a 1.3-3 log10 decrease in SIV replication [84]. 
Animals homozygous for the Q allele show the opposite pattern and are known to be more susceptible to 
infection [12]. The CypA allele exerts restriction directly on SIVsmE041, SIVstm, and SIVsmE543-3 
[12,79]. SIVmac251, on the other hand, is known to be unaffected by the TRIM5 polymorphisms 
regardless of the route of exposure, previous vaccination, viral dose, and protective MHC class I 
genotypes [83]. With respect to humans, these polymorphisms are not found in huTRIM5α; and while 
huTRIM5α is polymorphic, the polymorphisms are generally not associated with clinical disease, 
although other studies suggest otherwise [75,87,88,89].  
 The effect of TRIM5 polymorphisms applies to specific SIV strains (an outline for the 
derivation of each SIV strain is found in Appendix A). For example, studies have shown that SIV strains 
not adapted to rhesus macaques (SIVsmE660, SIVsmE041, and SIVsmE543) are easily restricted by 
TRIM5TFP whereas the highly adapted SIVmac251 and SIVmac239 are generally unaffected by TRIM5α 
restriction regardless of the TRIM5 allele [12,80]. The primary difference lies in the capsid sequence of 
the TRIM5α binding site. Unlike the other RFs, a lentiviral-encoded antagonist for TRIM5α does not 
exist. The virus has evolved to escape TRIM5α restriction by mutating the TRIM5α binding site in the 
capsid to decrease the affinity of the interaction [3,12]. Several studies have pinpointed two critical 
regions for TRIM5α binding: amino acids 89-LPA-91 and R97 (according to the SIVmac239 capsid 
sequence) [12,84,90]. TRIM5α binds to these regions of the capsid and any mutation in these sites can 
hinder TRIM5α binding and restriction. The SIVsm strains are easily restricted by TRIM5α because they 
encode 89-LPA-91 and R97. However, both SIVmacs evolved a capsid sequence that expresses 89-QQ-
90 instead of LPA and S97 instead of R [12]. These changes are potent enough to abrogate TRIM5α 
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binding to the viral capsid. In fact, studies show that TRIM5α alleles have no significant effect on 
SIVmac251 replication in vivo and disease progression despite challenge dose and prior vaccination [83]. 
It was suggested that the SIVmac capsid became adapted to counter TRIM5 restriction in comparison to 
the original SIVsm strain [12]. In fact, it is this adaptation that led to the emergence of the highly 
pathogenic SIVmac strain [12]. TRIM5α was therefore posited to be an important RF that can block 
cross-species transmission, limiting the early stage of virus replication. 
1.9.3 Tetherin 
 Tetherin is a unique single-pass type II membrane protein with three domains: a cytoplasmic tail, a 
transmembrane domain (TM), and an extracellular domain [91]. Its uniqueness stems from its integration 
within the cellular membrane by both the N-terminal TM domains and the C-terminal 
glycophosphatidylinositol (GPI) anchor [92]. Tetherin is localized in the plasma membrane lipid rafts, 
trans-Golgi network, and endocytic compartments [93]. Its localization on plasma membrane lipids rafts 
is naturally advantageous since virions bud from lipid rafts [6]. Specifically synthesized in the 
endoplasmic reticulum (ER), tetherin shuttles between the ER, trans golgi network (TGN), and the 
surface membrane and is continuously recycled [94]. Interestingly, tetherin recognizes one highly 
conserved and immutable structure, the virion membrane, and causes retention of budding virions [92]. 
Consequently, tetherin is non-specific and is able to restrict all retroviruses in addition to others such as 
filoviruses and paramyxoviruses [91]. It exists as a parallel dimer linked through disulfide bonds [94]. 
This dimerization facilitates efficient restriction by allowing one tetherin to remain bound to the cell 
membrane and the second tetherin to embed in the budding virion membrane. During virion budding, 
tetherin is inserted into the virion envelope and bridging between the host and viral lipid bilayers occurs, 
causing retention of the virion [95]. After tethering, the virions can be endocytosed for eventual 
degradation [91]. The unique topology of tetherin distinguishes it from other RFs. Studies show that 
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proteins with similar topology to tetherin but with completely different genetic sequences, “artificial 
tetherin,” still allow virion retention, indicating the importance of tetherin’s overall structure [30,92,95].  
  Naturally, tetherin functions in a cell as a ligand for the pDC ILT7 receptor to 
downregulate type I IFN production and thereby regulate immune activation [96]. While tetherin is potent 
solely as a tetherer of virions, it can also augment the host immune response. Virion retention by tetherin 
is believed to enhance antibody opsonization, complement deposition, and recognition by phagocytes and 
NK cells [91]. Tetherin can specifically allow better antigen presentation on MHC class II molecules after 
virion endocytosis and degradation. However, newer studies have also revealed tetherin may function as a 
viral sensor by recognizing virions and inducing a signaling pathway to enhance NFκb activation and 
inflammatory cytokine secretion to alert the immune system [97].  
 While tetherin is effective against a wide range of viruses, it is highly species-specific 
with respect to antagonism by viral proteins. Unlike the other RFs, tetherin can be combated by several 
viral proteins, depending on the viral strain. Specifically, tetherin is restrictive against HIV-1 and SIV but 
is efficiently antagonized by Vpu and Nef, respectively. These differences lie in the genetic makeup of 
each virus: HIV-1 encodes Vpu whereas SIV does not. Additionally, a five amino acid deletion in the 
cytoplasmic tail of human tetherin important for binding to Nef abrogates its ability to be antagonized by 
SIV Nef [98,99]. Rhesus tetherin, on other hand, is not affected by HIV-1 Vpu due to differences in the 
sequence of the TM domain [98]. However, both human and rhesus tetherin block viral release in the 
same fashion [100]. The variability in tetherin antagonism emphasizes the remarkable plasticity of the 
lentiviral genomes in combating RFs [100]. 
 The presence of the antagonists strongly cripple tetherin’s restrictive function. Vpu can 
decrease steady-state levels of cell-surface tetherin but can also mediate its degradation in endosomal 
compartments [94]. Through the recruitment of the E3 ligase complex, Vpu ubiquitinates the TM domain 
of tetherin and removes it from the cell surface. Since Vpu is localized primarily in the TGN, it can also 
contribute to the sequestration of tetherin that is being shuttled from the TGN to the plasma membrane 
[94]. In contrast, SIV Nef is localized at the cytosolic face of the plasma membrane and can downregulate 
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surface tetherin levels but does not reduce the overall protein level in the cell [98,101]. Specifically, Nef 
binds to the cytoplasmic tail of tetherin and recruits the AP-2 clathrin adaptor complex for tetherin 
downregulation.  
1.9.4 SAMHD1 
 Sterile alpha motif and HD domain 1 (SAMHD1) is a cellular protein with dNTPase activity and is 
particularly found in myeloid cells [102]. The SAM domain is specifically involved in protein-
protein/nucleic acid interaction while the HD domain functions as the nucleotidase [103]. The discovery 
of SAMHD1 came about after the observation that monocyte-derived macrophages (MDMs) and DCs are 
inefficiently infected by HIV-1. Specifically, SAMHD1 was discovered to hydrolyze intracellular dNTPs 
needed for retroviral reverse transcription [102]. It is particularly effective in that it depletes the available 
dNTP pool to concentrations lower than the threshold necessary for viral cDNA synthesis. Natuarlly, 
SAMHD1 functions as a negative regulator of the innate immune response by preventing the 
accumulation of retrotransposon DNA in order to inhibit activation of the innate immune response [102]. 
Mutations in SAMHD1 are associated with Aicardi-Goutières syndrome, a rare disease characterized with 
overproduction of IFNα and immune activation [102]. A recent study revealed that the restrictive ability 
of SAMHD1 is governed by a phosphorylation site and not by its dNTPase activity [104]. They 
specifically demonstrated that the enzymatic activity of SAMHD1 is not sufficient to prevent HIV-1 
replication and that phosphorylation at residue T592 may allow interaction with an unknown cofactor to 
effectively restrict HIV-1. 
 Unlike the other RFs, SAMHD1 does not have a particular viral target. In essence, 
SAMHD1 functions to non-specifically lower cellular dNTPs levels to create an antiviral environment 
against a range of retroviruses [102]. This raises the question of how the cell is not adversely affected by 
lower dNTP levels needed for basic cellular functions. The key is in the expression of SAMHD1 in non-
dividing or terminally differentiated cells, which do not require high levels of dNTPs [102]. While 
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lymphoid cells do express SAMHD1, levels are much higher in DCs followed by MDMs [102]. However, 
a recent report revealed high SAMHD1 expression in resting CD4+T cells, a cell type highly resistant to 
HIV-1 infection [105] . 
 SAMHD1 is antagonized by Vpx, a protein found only in the HIV-2-SIVsm lineage 
[102]. Vpx binds to SAMHD1 and mediates its ubiquitination and degradation. Conveniently, Vpx is pre-
packaged in a virion and is ready to reverse SAMHD1’s activity in the target cell [102]. Although HIV-1 
does not encode Vpx, studies propose that SAMHD1 may actually serve to benefit HIV-1 by allowing the 
avoidance of activation of the cytoplasmic sensors and inflammatory cytokine production [102]. HIV-1 is 
able to withstand SAMHD1’s effect despite the lack of Vpx by encoding a reverse transcriptase with a 
low Michaelis constant (Km) [103]. In other words, HIV-1 RT has a high affinity for dNTPs and is able to 
locate them even when dNTP levels become limited [103]. Without Vpx, studies show SAMHD1 causes 
reduced peak virus loads [103]. Additionally, infection with SIV lacking the Vpx gene causes impaired 
viral dissemination and disease progression in macaques [103]. 
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1.9.5 Schlafen 11 
 Schlafen 11 (SCHL11) is a member of the SLFN gene family commonly expressed in lymphoid tissue 
and known to regulate T cell development and cell growth [32,106,107]. This family of proteins is among 
the common ISGs induced after pathogen exposure [31]. Discovered in 2012, SCHL11 is the newest 
addition to the RF repertoire and was linked to a potent block in the late stage of HIV-1 replication. 
Specifically, it was found to bind to tRNAs and downregulate the expression of viral proteins by 
eliminating rare tRNA codons needed for HIV-1 protein translation [31]. In other words, SCHL11 has a 
late inhibitory effect by hindering viral protein translation and therefore virion production. Lentiviruses 
have high levels of the “A” nucleotide in their genome and SCHL11 exploits the viral codon bias by 
specifically sequestering the rare viral tRNA codons with an A/U in the third position [31]. Specifically, 
the GTA codon is the least used codon in human protein translation while it is the most used codon in 
HIV-1 protein translation [108]. Therefore, SCHL11 acts during the rate limiting step of HIV-1 protein 
translation by eliminating already rare tRNA codons needed for HIV-1 translation [31]. 
 Compared to the other RFs, little is known about the behavior of SCHL11 in different 
immune cell subsets and in response to infection. Specifically, it is completely unknown how SCHL11 
behaves in SIV-infected rhesus macaques. To date, no one has examined the role of SCHL11 in the 
context of SIV infections and this project is specifically geared to provide insight on this aspect. 
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Table 1. Overview of RF function. 
 
 
 
1.10 SIV/DELTAB670 
SIV/DeltaB670, the virus strain used in this study, was discovered in 1986 by Michael Murphey-Corb in 
a rhesus macaque displaying signs of lymphadenopathy [109]. Specifically, SIV/DeltaB670 was derived 
from a sooty mangabey with naturally-acquired leprosy and was passaged through two rhesus macaques 
(Figure 8) [110]. This isolate is highly pathogenic and can cause death in rhesus macaques within a 
median range of 289 days [22,111]. Additionally, the SIV/DeltaB670 stock consists of a swarm of 
genetically distinct viral sequences similar to HIV-1 [112]. Evaluation of the hypervariable V1 region in 
the Env gene of SIV/DeltaB670 revealed the presence of >23 genotypes [111]. 
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 In my study, the rhesus macaques were challenged intrarectally with repetitive, low 
doses of SIV/DeltaB670. The virus stock used for the challenge was obtained by co-culturing a lymph 
node homogenate from rhesus macaque B670 and primary human PBMC (huPBMC) and further 
expanded in the PBMC of two rhesus macaques with the CypA/CypA TRIM5 genotype.  
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Figure 8. Derivation of the SIV/DeltaB670 challenge stock virus. 
Each arrow indicates virus passage in vivo in a monkey or in vitro in PBMC. Animal numbers are noted. 
SM: sooty mangabey, RM: rhesus macaque, LN: lymph node. Blue box indicates isolation of the first 
SIV/DeltaB670 virus.  
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2.0  MATERIALS AND METHODS 
2.1 ANIMAL CARE 
Eight Indian-origin rhesus macaques ranging in age from 3-7 years were obtained from an 
approved vendor (Three Springs Scientific, Perkapsie, PA) and housed at the University of 
Pittsburgh primate facility (RIDC, Pittsburgh, PA). The animals were housed in accordance with 
the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) and with the approval of the University of Pittsburgh’s Institutional Animal Care 
and Use Committee (IACUC) standards/regulations. Animals were cared for by competent 
veterinary and animal caretaker staff. Ketamine anesthesia was used throughout experimental 
procedures and any discomfort or pain was alleviated by appropriate use of analgesic agents at 
the discretion of the attending veterinarian. Animals were monitored monthly for signs of disease 
by examining CD4+ T cell counts, weight, and evidence of opportunistic infections. Humane 
euthanasia was performed in accordance with guidelines as established by the 2007 American 
Veterinary Medical Association Guidelines when clinical AIDS or signs of fatal disease were 
observed. 
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2.2 ANIMAL CHALLENGES 
Each animal was rectally challenged on a weekly basis with 1mL cell free SIV/DeltaB670 (106 TCID50). 
Briefly, sedated animals  (10mg/kg Ketamine i.m.) were positioned in sternal recumbence and inoculated 
via atraumatic insertion of a 3-ml syringe (lubricated with Surgilube®) approximately 5 cm into the 
rectum. The inoculum was contained in 1.0 ml of saline. The inoculation was slowly pushed in for a full 
minute; the syringe left in place for five minutes and the animal left in sternal recumbence for a total of 15 
minutes. Animals were initially challenged with 103 TCID50 of the SIV/DeltaB670 stock but were 
challenged with 10-fold more virus (104 TCID50) for the remaining five challenges. Challenges were 
terminated when virus was detectable in the plasma.  Blood (3-10mls) was collected twice a week from 
each animal until they reached a viral set point.  
2.3 SAMPLE COLLECTION 
Duodenal biopsies were obtained by an endoscope (4 days prior to each of the first three rectal challenges 
and 3 days later) and collected in 1ml TRIzol and stored at -80°C. Inguinal lymph nodes (ILNs) were 
surgically removed (4 days prior to each of the first three rectal challenges and 3 days later) and 
immediately processed for mononuclear cell purification. Fifteen to eighteen pinch biopsies of the rectal 
vault were obtained four days prior to the 6th rectal challenge and 3 days later. The duodenum was 
specifically sampled due to accessibility by an oral endoscope, ease of sampling without causing harm to 
the animal, and relevance to understanding mucosal response to SIV infection. The ILNs were 
specifically obtained due to the location and ease of repetitively removing peripheral LNs without the 
animal undergoing surgery at each time point of sampling. 
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2.4 PLASMA VIRUS LOADS 
Viral RNA was extracted from plasma using TRIzol (Ambion) and RT-PCR was performed as previously 
described using primers specific for the viral long terminal repeat [113]. RT-PCR was performed on a 
Prism 7700 (Applied Biosystems) using external standards with an 8-log range. Final values were 
extrapolated from the standard curve and were expressed as RNA copies/ml plasma. Sensitivity threshold 
for this quantitative assay was ~50 copies. 
2.5 MONONUCLEAR CELL (MNC) PURIFICATION 
PBMC were isolated by Ficoll-Paque (Pharmacia) density barrier centrifugation from rhesus macaque 
blood samples treated with ACD and were either viably frozen in liquid nitrogen or pelleted and frozen at 
-80°C. Mononuclear cells (MNC) were isolated from inguinal lymph nodes by teasing and soaking in 
10% RPMI 1640 [supplemented with 15% fetal bovine serum, penicillin-streptomycin (100U/ml), L-
glutamine (2mM), HEPES buffer solution (10mM)] followed by straining to obtain purified mononuclear 
cells. After several washes with 10% RPMI, purified MNCs were viably frozen in liquid nitrogen.  
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2.6 CELLULAR RNA EXTRACTION 
Total RNA was isolated from viably frozen PBMC/ILN or frozen PBMC pellets using TRIzol (Ambion). 
RNA was isolated from the duodenal biopsies by first grinding the tissue with disposable tissue grinders 
and adding 1ml TRIzol. The Turbo DNA-free kit (Ambion) was used to purify the RNA and remove 
genomic DNA. RNA concentration was measured on the 2000c Nanodrop spectrophotometer (Thermo 
Scientific) and RNA purity and integrity was verified using the RNA 6000 Pico kit on the Agilent 2100 
Bioanalyzer (Agilent Biotechnologies).  
2.7 V1 ENVELOPE SEQUENCING 
Plasma viral RNA during acute infection was extracted with TRIzol (Ambion) and the V1 hypervariable 
region in the envelope was reverse transcribed. The RNA from the viral inoculum was also extracted 
using TRIzol (Ambion) and reverse transcribed. Nested PCR amplification of the V1 region of the cDNA 
was performed as described (Table 2) [112]. Similar PCR conditions were used for both rounds of PCR 
(Table 3). PCR products from 2-4 individual amplifications of the viral inoculum were pooled prior to 
cloning. The ~200bp amplified DNA sequence was gel-purified (Wizard PCR Preps DNA Purification 
System-Promega). PCR products were cloned into a vector (pCR 4-TOPO) using the TOPO TA Cloning 
Kit (Invitrogen). Approximately 10-26 clones were isolated and purified using the Wizard Plus SV 
Minipreps (Promega). Cloning and purification was performed as described in the kits’ manuals and sent 
for sequencing at Genewiz Inc., NJ. Geneious Pro Software (version 5.5.2) was used to align the V1 
sequences and SeqPublish (Los Alamos National Laboratory) was used to prepare the formatted 
alignment. Each V1 nucleotide sequence was BLASTED® (NIH) to determine the identity of the clone as 
previously published [112].  
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Table 2. Protocol for V1 Env PCR amplification. 
 
Reagent Volume (uL) 
10X Hotmaster Buffer (5 Prime) 10 
Forward Primer (20pmol) 1 
Reverse Primer (20pmol) 1 
dNTPs (Applied Biosystems) 8 
Hotmaster Taq DNA polymerase (5 Prime) 0.6 
Nuclease Free Water 75.4 
DNA 2 
Total Volume 100 
 
 
Table 3. PCR conditions for V1 Env amplification. 
 
Step Temperature (°C) Time 
1. Initial denaturation 94 2 min 
2. Denaturation 94 15 sec 
3. Annealing 55 15 sec 
4. Extension 72 30 sec 
5. Final extension 72 10 min 
Hold 4 ∞ 
Steps 2-4 repeated 35 cycles 
 
2.8 RF EXPRESSION ASSAYS 
A maximum of 2ug total cellular RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). A total of 25ng cDNA was used for RT-PCR amplification of 
each gene and reactions were performed in duplicate. Positive controls and no template controls were 
included in each assay. The assay IDs for the pre-developed Taqman assays (Applied Biosystems) are 
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displayed in Table 4. Each assay was specific for rhesus macaques and amplified exon-exon regions and 
did not detect genomic DNA. RT-PCR was performed on the 7900 HT Fast Real-time PCR system 
(Applied Biosystems) using the recommended reagents (Taqman Fast Universal PCR Mastermix 2X, no 
AmpErase UNG-Applied Biosystems) and conditions supplied with the Taqman assays. Reaction 
protocol is shown in Table 5. The TRIM5α Taqman assay listed in table 4 was used throughout the entire 
study. However, since this TRIM5α assay detects exons 7-8, which is absent in the TRIMCypA allele in 
one macaque (R701), we used another TRIM5α Taqman Gene Expression assay (Rh02788626_m1) that 
detects exons 1-2, a non-polymorphic site in both TRIM5α and TRIMCypA. Relative TRIM5 expression 
levels from both TRIM5 Taqman assays showed minor differences and therefore only the TRIM5α 
Taqman assay that detected exon 7-8 was used throughout the study. 
 
 
Table 4. Applied Biosystems Taqman Assay IDs. 
 
Gene Assay ID 
APOBEC3G Rh02788475_m1 
TRIM5α Rh02788631_m1 
Tetherin  Rh02848328_m1 
SAMHD1 Rh01122752_m1 
Schlafen 11 Rh02885088_m1 
Mx1 Rh02842279_m1 
IFNγ Rh02788577_m1 
TBP Rh00427620_m1 
HPRT Rh02827360_m1 
β2M Rh02847367_m1 
βGus Rh02788764_m1 
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Table 5.  RF assay RT-PCR protocol. 
 
Reagent Volume (uL) 
20X Taqman Gene Expression Assay 1 
2X Universal PCR Mastermix (no UNG) 10 
Nuclease Free Water 8 
25ng cDNA 1 
Total Volume 20 
 
 
 
All genes were validated for efficiency prior to the start of the assay by creating serial dilutions of 
a control cDNA sample (Appendix B). Linear regression analysis was performed to evaluate assay 
linearity (R2) and efficiency (1-10 -1/slope).  All lines had R2 values >0.99 indicating linearity. Slopes were 
between -3.3 and -3.6 and therefore efficiency was >90%. A total of four endogenous controls were used 
at the start of the assay (TBP, HPRT, β2M, βGus) to determine the two most stable genes. Raw RT-PCR 
data were analyzed first by SDS RQ manager (version 2.3, Applied Biosystems) to obtain the Ct values. 
DataAssist Software (Applied Biosystems, version 3.01) was used to determine the top two most stable 
genes according to the scores calculated (the lower the score, the more stable the endogenous control). 
DataAssist also calculated 2-ΔCt values. Raw 2-ΔCt values were then multiplied by 1000 to obtain relative 
expression for each gene after normalization to TBP and HPRT. Fold change in expression was calculated 
by dividing the relative expression at each time point by the basal expression (four days prior to the first 
challenge).   
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2.9 IDENTIFICATION OF TRIM5 POLYMORPHISMS 
Genomic DNA was extracted from PBMC using the DNeasy Blood and Tissue kit (Qiagen). TRIM5α 
was PCR amplified with primers and PCR conditions as described [12]. The PCR protocol is shown in 
table 6. Gel-purified DNA of ~500bp (Wizard PCR Preps DNA Purification System-Promega) was 
cloned into the pCR 4-TOPO vector using the TOPO TA Cloning Kit (Invitrogen) and four clones were 
isolated and purified using the Wizard Plus SV Minipreps (Promega). Cloning and purification was 
performed as described in the kits’ manuals. The clones were sent for sequencing at Genewiz Inc., NJ. 
Geneious Pro Software (version 5.5.2) was used to align sequences and identify polymorphisms in the 
339-341 amino acid region. Animals were either homo/heterozygous for TFP, Q, or CypA. The 
TRIMCypA allele was identified according to the presence of a published SNP (G to T substitution) in 
intron 6 [114].  
 
 
Table 6. TRIM5α PCR amplification protocol. 
 
Reagent Volume (uL) 
Accuprime Supermix II (Invitrogen) 25 
Forward Primer (10uM) 1.5 
Reverse Primer (10uM) 1.5 
Nuclease Free Water 17 
Undiluted DNA 5 
Total Volume 50 
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2.10 SEQUENCING OF TRIM5A CAPSID BINDING REGION 
Viral RNA from plasma was isolated by TRIzol (Ambion) and reverse transcribed using random 
hexamers (Applied Biosystems). Viral RNA was directly isolated (TRIzol-Ambion) from the inoculum 
stocks and reverse transcribed. Two rounds of PCR were performed to amplify the 546bp N-terminal 
region of the TRIM5α binding site in the capsid. The following primers were used for round 1 PCR: 
Forward-5’-ATG GGC GTG AGA AAC TCC G-3’, Reverse-5’-CAA GCC GTC AGC ATT TCT TCT 
AG-3’. The following were the primers for round 2 PCR: Forward-5’ AAG CCC TAG AAC ATT AAA 
TGC-3’, Reverse-5’-GCA ATC GTT AGC ATT TTG AAT CAG-3’. The reaction protocol and 
conditions are shown in Tables 7 and 8, respectively. The amplicon was excised, gel-purified, and cloned 
into the TOPO TA cloning vector (Invitrogen). Two to four clones were selected, plasmid-purified, and 
sent for sequencing (Genewiz, NJ). Geneious Pro Software (version 5.5.2) was used to align capsid 
sequences. 
 
 
Table 7. Protocol for PCR amplification of the TRIM5α capsid-binding region. 
 
Reagent Volume (uL) 
10X Hotmaster Buffer (5 Prime) 5 
Forward Primer (10uM) 0.5 
Reverse Primer (10uM) 0.5 
dNTPs (Applied Biosystems) 4 
Hotmaster Taq DNA polymerase (5 Prime) 0.3 
Nuclease Free Water 34.7 
Undiluted DNA 5 
Total Volume 50 
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Table 8. PCR conditions for amplification of the TRIM5α capsid-binding region. 
 
Step Temperature (°C) Time 
1. Initial denaturation 94 2 min 
2. Denaturation 94 20 sec 
3. Annealing 55 20 sec 
4. Extension 72 30 sec 
5. Final extension 72 7 min 
Hold 4 ∞ 
1st Round of PCR: steps 2-4 repeated 35 cycles 
2nd Round of PCR: steps 2-4 repeated 30 cycles 
 
 
2.11 MHC CLASS I GENOTYPING 
Total RNA from PBMC of the eight animals was extracted and sent to the Wisconsin National Primate 
Research Center Genetics Service Unit (University of Wisconsin-Madison, USA) for MHC class I 
genotyping. 
2.12 STATISTICAL ANALYSIS 
Statistical analysis was performed using Prism 6.0b for Mac OS X and the appropriate statistical tests are 
listed under each figure. P<0.05 was considered significant. 
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3.0  STUDY OVERVIEW 
3.1 CURRENT KNOWLEDGE 
 An association between expression of RFs and delayed disease progression has been shown in HIV+ 
humans. HIV-exposed seronegative individuals have significantly higher huA3G levels in PBMC and 
cervical tissue when compared to healthy controls, and PBMC of long-term nonprogressors (LTNPs) 
have significantly higher A3G levels than those of non-controllers [54,115,116,117]. Additionally, higher 
pre-infection A3G levels inversely correlate with the HIV viral set point [118].  With respect to tetherin, 
an association between higher tetherin levels and HIV-1 disease progression is observed [119], while in 
another, induction of tetherin expression during patient treatment with IFNα correlates with a reduction in 
HIV-1 virus burden [120].  Others show tetherin overexpression inhibiting particle release despite the 
presence of a viral antagonist [40]. These findings are further supported in rhesus macaques where higher 
A3G expression correlates with lower virus loads, increased survival, and protection from subsequent 
mucosal challenge [121,122,123]. While studies show higher TRIM5α expression associated with 
significant antiviral activity, the longitudinal expression of TRIM5α has not been examined, particularly 
in relation to viremia [124]. More importantly, less is known about SAMHD1 and SCHL11 expression in 
response to infection, especially with respect to the SIV macaque model.  
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3.2 GAPS OF KNOWLEDGE 
 While a significant contribution has been made in the field regarding the in vitro and in vivo role of these 
RFs, several questions remain to be answered. It is unclear if one or all RFs work in concert to provide 
optimal control early after viral exposure. Similarly, it is unknown whether animals with inherently lower 
basal RF levels are at a higher risk of infection.  While it is established that RF (A3G) expression is 
inversely correlated with HIV/SIV viremia [54,121], analyzing the in vivo behavior of these RFs over a 
day to day time course during exposure can allow us to decipher how the host responds to virus early after 
exposure and when the expression threshold is reached to allow a host to succumb to disease. Whether 
these RFs are differentially induced in the mucosa in comparison to the periphery of infected macaques 
and whether induction fluctuates after each mucosal challenge is not known. Better understanding of how 
these RFs behave pre- and post-viral exposure is necessary to harness their innate ability to block the 
virus through gene therapy or vaccines that specifically upregulate these genes to arm the immune system 
prior to exposure. In other words, RFs may have a significant, understudied ability to hinder virus 
replication if expressed at higher levels prior to exposure. This speculation may be more evident with 
repetitive, low dose rectal challenges, which has not been examined previously. 
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 To address these gaps of knowledge regarding the in vivo behavior of the five RFs, a 
thorough time course analysis of their expression in the mucosa and the periphery was performed by 
analyzing basal and induction levels and correlating these levels to susceptibility to infection in a cohort 
of eight Indian-origin rhesus macaques. I hypothesized that higher basal RF expression may exert a 
protective effect by delaying systemic infection. The two overarching questions that framed my work 
were: 1) why do some hosts remain persistently uninfected despite repeated exposure; and 2) could RF 
expression contribute to that variability. Therefore, I set out to understand whether inherent animal 
differences such as tissue-specific basal RF levels, early RF induction, maximum RF induction, and 
TRIM5α genotype all play a role in determining susceptibility to infection. I also wanted to determine if 
the changes seen in the blood mirror those seen in the mucosa (gut), the primary replication site for 
HIV/SIV [125].  
3.3 PROJECT OVERVIEW 
 A cohort of eight Indian origin rhesus macaques were subjected to weekly low dose rectal challenges with 
the primary pathogenic isolate, SIV/DeltaB670 and evaluated for systemic infection. Pre and post-
exposure mRNA levels of the five known lentiviral RFs (TRIM5α, A3G, Tetherin, SAMHD1, SCHL11) 
in addition to Mx1 and IFNγ were measured in each animal at 3-day intervals. Animals were divided into 
groups based on their susceptibility to infection and RF levels were monitored over time to analyze how 
expression of these RFs affects infection. Since TRIM5 polymorphisms impart a significant inhibitory 
effect on the replication of several SIV strains, I analyzed the TRIM5 polymorphisms in the cohort and its 
impact on an animal’s susceptibility to infection with SIV/DeltaB670. Specifically, I examined whether 
the TRIM5α-capsid binding region in SIV/DeltaB670 exhibited signs of resistance to TRIM5α-mediated 
restriction as other SIV strains have shown.  
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3.4 SPECIFIC AIMS 
The intrinsic ability of RFs to block lentiviral replication immediately post viral entry has refocused the 
attention of the field. Although some studies have examined specific expression of some RFs and linked 
their expression with lower viremia and slower disease progression, the vast majority of RF studies have 
examined the molecular behavior of each RF in vitro using specific cell lines or immune cell subsets. 
Very few studies have conducted a longitudinal analysis of RF expression in vivo to understand how these 
levels can impact susceptibility to infection. More importantly, no studies have examined basal RF 
expression in rhesus macaques and its potential in delaying systemic infection. By evaluating expression 
changes of these RFs in vivo, we are getting a closer look at the host’s response to infection and 
understanding whether basal and early induction of the RFs serve to protect the host from the harmful 
consequences of an established infection. While prevention of HIV/SIV acquisition is of prime 
importance, prevention of an established infection can be more relevant and achievable by further 
understanding the behavior of these RFs prior to exposure. 
 
Aim 1: Compare basal RF expression in the mucosa and periphery of rhesus macaques exhibiting 
differences in susceptibility to infection.  
Hypothesis: Basal RF expression positively correlate with resistance to systemic infection. 
A) Quantify basal levels of A3G, TRIM5α, tetherin, SAMHD1, and schlafen 11 in PBMC, duodenum, 
and ILNs to evaluate tissue-specific expression. Approach: Basal cDNAs from rhesus macaque PBMC, 
duodenal biopsies, and ILN purified cells were subjected to RT-PCR to determine relative expression 
levels of each gene using pre-developed Taqman assays.  
B) Evaluate the relationship between basal RF expression and an animal’s susceptibility to infection. 
Approach: Tissue-specific relative RF levels from Aim1a were compared to the number of challenges 
required for systemic infection using statistical tests and linear regression analysis. 
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Aim 2: Examine the impact of RF induction on a host’s susceptibility to infection. 
Hypothesis: Early RF induction delays systemic infection and controls virus replication.   
A) Measure longitudinal RF induction to determine the relationship between early, maximum, and late 
RF induction and an animal’s resistance to infection. Approach: Longitudinal RF induction in PBMC 
post first viral challenge were determined by calculating the fold change in RF expression relative to basal 
levels.   
B) Determine if RF induction seen in the blood mimics that seen in the mucosa. Approach: PBMC RF 
induction as determined in Aim 2a was compared to RF induction in the duodenum. 
 
Aim 3: Investigate the in vivo role of TRIM5 polymorphisms. 
Hypothesis: TRIM5 polymorphisms exert no protective effect on rhesus macaques rectally challenged 
with SIV/DeltaB670.  
A) Determine the TRIM5α genotype of each animal and its impact on susceptibility to infection and 
disease progression with SIV/DeltaB670. Approach: Sequenced the C-terminal B30.2/PRYSPRY 
domain of the eight rhesus macaques and identify the polymorphism present in amino acid region 339-
341. To identify the presence of the CypA allele, a SNP in intron 6 was analyzed for the G>T 
substitution. The number of challenges required for systemic infection were compared to each animal’s 
TRIM5 genotype to determine if TRIM5 polymorphisms impact susceptibility to infection. The impact of 
TRIM5 polymorphisms on disease progression were analyzed by correlating to the viral set point for each 
animal.  
B) Determine SIV/DeltaB670’s susceptibility to TRIM5α-mediated restriction by examining the TRIM5 
binding site in the viral capsid.  Approach: Sequenced the N-terminal region of the TRIM5α binding site 
in the capsid of the challenge virus and aligned to several well-studied SIV strains and various HIV-1 
subtypes. 
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3.5 SIGNIFICANCE 
 Why certain individuals succumb to HIV infection, while others remain persistently uninfected despite 
repeated exposure has been a puzzling observation for scientists. The same scenario is seen with non-
human primates that remain persistently uninfected after repetitive mucosal challenges. Additionally, 
natural hosts of SIV virus (ex: African green monkeys infected with SIVagm) are able to prevent disease 
progression while non-natural hosts (ex: rhesus macaques infected with SIVmac) develop an AIDS-like 
disease [126,127]. Many speculations have been made proposing differences in the mounted immune 
response or host genetics as the cause. During infection, the host has three forms of defense: intrinsic 
immunity (host restriction factors), innate immunity, and adaptive immunity [3,128]. Previous HIV/SIV 
studies have focused predominately on host adaptive immune responses to the virus in the peripheral 
organs/blood. While significant progress has been made in these aspects, more focus needs to be directed 
toward the intrinsic/innate immune system to elucidate possible mechanisms of virus inhibition in the 
mucosa prior to dissemination and further CD4+ T cell depletion.  
 An intense amount of research has linked the power of host RFs in the inhibition of 
HIV/SIV replication both in vitro and in vivo. Again, the primary reason HIV-1 cannot replicate in rhesus 
macaques is due to the restrictive function of rhesus TRIM5α and A3G [53,62,64,81,124]. Specific 
mutations in these RFs can influence the corresponding viral antagonists’ function and change the virus’s 
ability to adapt to a new host [5,63,129]. Such powerful conclusions should prompt rigorous research 
regarding the role of RFs early and late during an infection. It is also unknown whether these RFs are 
differentially expressed and induced in the mucosa in comparison to the periphery of infected macaques. 
Some studies in macaques have looked at RF expression changes in PBMC, but over a longer timeframe 
(weeks), while I believe it is critically important to analyze RF levels prior to exposure to understand their 
potential protective influence on the host. The significance of my study is threefold: 1) the ability to 
simultaneously measure the basal and induction levels of all five RFs throughout multiple exposures; 2) 
the ability to measure these changes directly in the mucosal and peripheral compartments; and 3) the 
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ability to monitor these changes in vivo. Additionally, studies have been limited to the in vitro antiviral 
ability of huSCHL11, but evidence examining its role in vivo, especially with respect to SIV, is lacking. 
Therefore, my study is the first to analyze SCHL11 expression in vivo after SIV infection and the first to 
specifically characterize the relationship of all five RFs both pre and post-exposure and their impact on an 
animal’s susceptibility to infection.  
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4.0  RESULTS 
4.1 OUTCOME OF REPETITIVE LOW DOSE RECTAL EXPOSURES  
Eight Indian-origin rhesus macaques received up to six low-dose rectal challenges at weekly intervals 
with an initial dose of 103 TCID50 of SIV/DeltaB670 and then 104 TCID50 during the last five challenges. 
Challenges were terminated for each animal after it became systemically infected. Three macaques had 
detectable viremia after two challenges (R700, R701, R702; susceptible to infection), two macaques had 
detectable viremia after three challenges (R703, R704; intermediately susceptible), while three macaques 
required 6-7 challenges before virus was detected in the plasma (R705, R697, R698; resistant to infection) 
(Figure 9). All three susceptible animals behaved similarly, with a peak in viremia of 106-107 RNA 
copies 10-14 days post their second rectal exposure, and a viral set point of 104-106 reached within 31-37 
days after the first viral exposure. These susceptible animals were sacrificed 37 days post first viral 
challenge for tissue collection.  Viremia was detected in the intermediate animals after the third challenge.   
Virus levels gradually increased to a maximum of 105 (R704) and 106 (R703) copies/ml plasma and 
decreased thereafter to a set point of 103 and 105 copies/ml plasma, respectively. Two of the resistant 
animals (R697 and R698) required 6 challenges to become systemically infected. Monkey R697 had the 
highest peak viremia of all 8 animals (108), while R698 displayed better control of virus replication. 
However, the viral set point in both R697 and R698 was indistinguishable from those achieved in the 
susceptible group. 
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Figure 9. Outcome of repeated, low-dose rectal challenges with SIV/DeltaB670. 
  Eight Indian-origin rhesus macaques received weekly low dose rectal challenges. Animals were initially 
challenged with 1cc cell-free SIV/DeltaB670 (TCID50=103) and then 10-fold more virus (TCID50=104) for 
the remaining five challenges.  Blood was collected twice a week and copies of viral RNA were 
quantified in plasma by qRT-PCR using external standards. Animals were divided into three groups based 
on the number of challenges required for systemic infection: susceptible (red); 2 challenges (R700, R701, 
R702), intermediate (green); 3 challenges (R703, R704), and resistant (blue); ≥6 challenges (R697, R698, 
R705). Red dotted line at 104 viral RNA copies indicates the threshold virus load (VL) associated with 
clinical disease in rhesus macaques. Arrows indicate time points of challenge.  Χ = sacrifice for tissue 
collection.  
 
 
 Of particular interest is R705, which developed a delayed, low-level transient viremia 
that was detectable 17 days after the 6th challenge. However, viremia was effectively controlled and virus 
was undetectable by day 72. R705 was exposed to a 100-fold higher dose of virus on day 107. Despite the 
high dose of virus, a low level of viremia was again detected that was transient; blips in viremia recurred 
thereafter without further challenge, with no more than 100 copies/ml of plasma persistently detected 235 
days into the study.  This animal was an elite controller, characterized by minimal levels of virus detected 
in the plasma and no signs of infection or disease. Altogether, these eight animals depicted the full 
spectrum of infection and disease previously described for SIV/DeltaB670, with 3 susceptible, 2 
intermediately susceptible, and 3 animals resistant to infection. These results demonstrated that the low 
dose rectal exposures in a cohort of 8 animals generated noticeable variability in macaque susceptibility 
to infection which will prove to be crucial in the upcoming experiments. 
 
4.2 COMPARISON OF TISSUE-SPECIFIC BASAL RF EXPRESSION 
Following sexual exposure, the gut and/or vaginal mucosa serve as the initial sites for virus replication, 
followed by further expansion and dissemination of the virus via the draining lymph nodes and blood 
[21,130]. Since lentiviral RFs are part of the intracellular intrinsic defense system, in that they cause 
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resistance to virus infection without previous signaling [3,30,36,37,38,39,40], it was important to analyze 
in vivo expression of these genes in the mucosal and peripheral compartments prior to viral exposure. To 
address this issue, we began by evaluating basal mRNA levels of Mx1, A3G, TRIM5α, SAMHD1, 
tetherin, and SCHL11 in each animal four days prior to the first rectal challenge. Three compartments 
were examined: PBMC, ILNs, and the duodenum. IFNγ mRNA levels were also measured to examine the 
relationship between RF expression over time and induction of adaptive immunity [34]. Expression of 
Mx1, a common ISG, was measured to serve as a positive control in my study since RFs are also ISGs 
[28,30,31,39,131]. Mx1 was particularly chosen because it is among the most potent, long-lasting 
antiviral genes solely induced by type I interferons [26,132]. Previous studies have examined Mx1 
mRNA levels in rhesus macaque PBMC and levels correlated with IFNα expression [121,132].  
 In general, RFs displayed higher mean basal expression in PBMC than in the ILNs and 
duodenum (Figure 10). Basal RF levels were more variable in PBMC compared to the ILNs and 
duodenum, with the latter two compartments displaying a tighter clustering of RF expression. Tetherin 
and SAMHD1 were more highly expressed than the other RFs in the three compartments (Figure 10C,E). 
SCHL11 expression was especially low in the three tissues compared to the rest of the RFs with levels 
ranging from 30-900 copies (Figure 10F). As expected for naive animals, baseline IFNγ levels were 
lower in all three tissues compared to the RFs and Mx1 (Figure 10G). Together, these data illustrate that 
RFs are constitutively expressed and exhibit tissue-specific expression, with higher levels primarily found 
in the blood versus the duodenum and ILNs.  
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Figure 10. Basal RF expression in PBMC, ILNs, and duodenum. 
Relative mRNA levels of (A) Mx1, (B) TRIM5α, (C) Tetherin, (D) A3G, (E) SAMHD1, (F) SCHL11 
and (G) IFNγ was determined in PBMC, inguinal lymph nodes (ILNs), and duodenal biopsies in the eight 
animals. Samples were obtained 4 days prior to the first exposure (basal levels) on all animals except 
monkey R700 from which PBMC was obtained on day 0 (day of first exposure) while duodenal and ILN 
samples were obtained 4 days prior to first exposure. Relative expression was determined using the ΔΔCt 
comparative method and values were normalized to endogenous controls TBP and HPRT. Horizontal 
lines denote means values. Each symbol indicates the mean value from one animal. 
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4.3 BASAL RF EXPRESSION AND SUSCEPTIBILITY TO MUCOSAL INFECTION 
AND DISEASE PROGRESSION 
 To understand whether intrinsic differences in basal ISG (A3G, TRIM5α, tetherin, SAMHD1, SCHL11, 
and Mx1) expression related to the observed variability in the cohort’s susceptibility to infection, RF 
expression in the susceptible, intermediate, and resistant groups were compared in the three compartments 
(Figure 11). In PBMC, there was a noticeable difference in basal Mx1 levels among the three groups with 
resistant animals exhibiting significantly higher levels of Mx1 (P=0.025) compared to the susceptible 
(Figure 11A). Remarkably, rhesus macaques resistant to infection also had significantly higher (P=0.01) 
basal TRIM5α levels in the blood versus the susceptible animals (Figure 11B). RF mRNA levels in ILNs 
displayed a similar pattern, with a significant difference in Mx1 expression among the three groups 
(P=0.025) and TRIM5α showing a trend toward significance (P=0.06).  A similar trend was also observed 
for the remaining RFs in the blood (tetherin, A3G, SAMHD1, and SCHL11), although these differences 
were not as pronounced as that observed for Mx1 and TRIM5α (Figure 11C-F). After TRIM5α and Mx1, 
the greatest trend was seen in PBMC tetherin and A3G expression (P=0.06, P=0.09, respectively), where 
resistant animals expressed higher basal levels of these two RFs than the susceptible (Figure 11C,D). 
Notably, the patterns seen in the PBMC and ILNs were not observed in the duodenum. 
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Figure 11. Tissue-specific basal RF expression and susceptibility to infection. 
Basal expression of (A) Mx1, (B) TRIM5α, (C) Tetherin, (D) A3G, (E) SAMHD1, (F) SCHL11 was 
measured as in figure 10. Samples were obtained 4 days prior to the first exposure (basal levels) on all 
animals except monkey R700 from which PBMC was obtained on day 0 (day of first exposure) while 
duodenal and ILN samples were obtained 4 days prior to first exposure. Animals were divided into 
susceptible (red), intermediate (green), and resistant (blue) groups according to figure 9. Mean +/- SD of 
basal mRNA values in each tissue are shown for each group. Significance was calculated using the 
Kruskal-Wallis test with Dunn's multiple comparison test. Asterisks indicate significance at P<0.05. P 
values indicating trends toward significance are shown. Each symbol indicates one animal. 
 52 
  A significant association between higher basal RF expression and resistance to mucosal 
infection was further confirmed by linear regression analysis. Tissue-specific basal ISG expression for 
each animal was plotted against the number of exposures required for systemic infection (Figure 12). A 
significant positive correlation was observed between basal A3G, TRIM5α, SAMHD1, and Mx1 levels in 
PBMC and resistance to infection (Figure 12A). This correlation was especially pronounced for TRIM5α 
(r2=0.85, P=0.001). Basal TRIM5α levels in the duodenum and ILNs were also positively correlated with 
the number of exposures required for systemic infection but were not significant (Figure 12B,C). 
Although higher tetherin and SCHL11 expression in PBMC did not significantly correlate with resistance 
to infection, a positive trend was observed (P=0.06, P=0.09, respectively) which was also seen for 
SCHL11 in the ILNs (P=0.08). No significant correlation between basal ISG expression and resistance to 
infection was observed in the duodenum. 
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Figure 12. Relationship between tissue-specific basal RF expression and resistance to infection. 
Basal ISG levels in (A) PBMC, (B) Duodenum, (C) ILNs were compared to the number of exposures an 
animal required for systemic infection. Samples were obtained 4 days prior to the first exposure (basal 
levels) on all animals except monkey R700 from which PBMC was obtained on day 0 (day of first 
exposure) while duodenal and ILN samples were obtained 4 days prior to first exposure. Each dot 
indicates one animal. Lines depict linear regression analysis with r2 and p values indicated next to each 
gene. Asterisks indicate significance with p<0.05. Genes without a p value were not significant or 
trending toward significance (p<0.09). 
 
 54 
 These data clearly revealed an association between higher basal RF levels and an 
animal’s resistance to infection. However, it was not clear whether higher basal RF levels could 
contribute to a lack in disease progression after infection. It is already established in the field that viral set 
point determines the extent of host disease progression [133]. As such, basal RF, Mx1, and IFNγ levels 
were examined in the three tissues and compared to each animal’s viral set point. Correlation analysis 
revealed no significant relationship between basal RF levels in the blood and ILNs and an animal’s viral 
set point and therefore disease progression (Figure 13). Interestingly, a negative correlation was observed 
between expression of all genes in the blood (except IFNγ) and viral set point, indicating the impact of 
higher RF levels in slowing disease progression (Figure 13A). A significant trend was observed in the 
duodenum, however, for TRIM5α (spearman r=-0.74, P=0.046) and less so for A3G (spearman r=0.71, 
P=0.057) (Figure 13B). It is important to note that TRIM5α expression in all three tissues was 
consistently negatively correlated with viral set point. This observation was not evident for the other RFs 
in all three tissues. 
 In summary, animals resistant to mucosal infection expressed higher basal ISG levels 
than those more susceptible to infection, with differences in the levels of Mx1 and TRIM5α significant 
with expression of the remaining RFs trending toward significance. These differences were strongest in 
the blood and followed by the ILNs, with expression in the duodenum varying only marginally among the 
three groups.  No significant association between basal ISG expression and disease progression was 
observed in either of the tissues. Only basal TRIM5α levels in the duodenum showed a significant 
negative correlation with viral set point, which may indicate its potential protective effect in the gut.   
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Figure 13. Relationship between tissue-specific basal RF expression and viral set point. 
Basal ISG and IFNγ levels in (A) PBMC (B) Duodenum (C) ILNs were plotted against an animal’s 
corresponding viral set point. Samples were obtained 4 days prior to the first exposure (basal levels) on all 
animals except monkey R700 from which PBMC was obtained on day 0 (day of first exposure) while 
duodenal and ILN samples were obtained 4 days prior to first exposure. Spearman correlation analysis 
was performed to evaluate the relationship between the two variables. Spearman r with two-tailed p 
values are indicated next to each gene for the three tissues. Asterisk indicate significance at p<0.05. P 
values tending toward significance were noted. Each symbol indicates one animal.  
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4.4 LONGITUDINAL ANALYSIS OF ISG INDUCTION IN PBMC 
 After examining pre-exposure RF levels in the blood, it was important to determine whether repetitive 
challenge induced RFs and whether induction in the blood correlated with resistance. A time course 
analysis examining RF induction in the blood post virus exposure was conducted for each animal over the 
series of repetitive rectal challenges. Longitudinal analysis was performed only in the blood and not the 
duodenum or ILNs due to the availability of blood samples throughout the time course. Induction levels 
are displayed as fold-change which was determined by dividing relative mRNA copy values at each time 
point with those at baseline (day -4 of the challenge series), with a 2 fold change serving as the minimum 
threshold.  These results are plotted in relation to virus loads.  
4.4.1 ISG time course in the susceptible animals 
 Transient induction of the six ISGs was observed in all susceptible animals during the acute viremic 
episode associated with systemic infection (Figure 14). As expected for genes induced by IFNα, high 
expression was observed at the first time point virus was detectable in the blood, but declined to basal 
levels 3-7 days later. A 5-fold induction of TRIM5α and a 7-fold induction of tetherin was observed for 
R700 on day 17 (Figure 14A). Induction of these two RFs was particularly higher than A3G, SAMHD1, 
and SCHL11. R701 had a 5-6 fold induction of tetherin and TRIM5α on day 14 while the other RFs were 
induced to a lower extent, about 3-5 fold (Figure 14B). RF expression remained high for R701 three days 
later with TRIM5α and tetherin showing persistently high induction among the rest of the RFs. R702 also 
had a 4-5 fold induction of TRIM5α, tetherin, and A3G on day 17, three days after the appearance of 
virus in the blood (Figure 14C). RF induction, however, quickly subsided after the initial viremia 
remaining below the 2-fold threshold for the three animals. As expected, Mx1 induction corresponded 
with RF induction in the susceptible animals. R700 had a 20-fold induction of Mx1 at the first viremic 
time point and levels increased to 50 fold three days later (Figure 14A). R701 and R702, on the other 
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hand, had a 40-fold induction of Mx1 during initial viremia that decreased to 30- and 5-fold, respectively 
(Figure 14B,C). Similar to the RFs, Mx1 levels were downregulated after initial viremia in the 
susceptible group, remaining below the 2-fold mark (Figure 14). IFNγ expression, on the other hand, 
remained well below the 2-fold threshold in the susceptible animals with no induction observed 
throughout the time course. Although the ISGs were induced during initial viremia, their induction levels 
did not appear to affect virus replication later in the time course. 
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Figure 14. Longitudinal analysis of RF and IFNγ induction in susceptible animals. 
The fold change in the relative expression of each RF, Mx1, and IFNγ in PBMC are plotted (A) R700, (B) 
R701, (C) R702. Samples were obtained 4 days prior to the first exposure (basal levels) on all animals 
except monkey R700 from which PBMC was obtained on day 0 (day of first exposure). Each gene is 
depicted by a different colored bar as indicated in the figure legend; plasma virus loads are shown by the 
black line and the right Y-axis.  Fold change was calculated by dividing the relative mRNA level at each 
time point by the constitutive level observed at baseline. Mx1 was not measured at all time points (R702 
day 3, all animals days 24-31). The black solid line indicates the threshold for the observed induction to 
be true. Asterisks next to day numbers indicate days of rectal challenge.  
 
 
 
4.4.2 ISG time course in the intermediate animals 
 Intermediate animals displayed transient RF induction similar to the susceptible group. Expression during 
the earlier time points (days 3-10) was below the 2-fold threshold (data not shown). RF induction for 
R703 and R704 occurred primarily on day 24 (10 days after the third rectal challenge) and after virus 
detection in the blood (Figure 15). Levels were downregulated thereafter. RF induction levels in the 
intermediate animals were much lower than the susceptible. A 4-fold induction of Mx1 was observed for 
R703 on day 21 which increased to 40 fold just three days later, corresponding with the 2-3 fold RF 
induction (Figure 15A). After day 24 for R703, levels remained below the 2-fold mark for all genes 
examined. R704’s time course was different from R703 in that IFNγ was persistently induced at 2-5 fold 
from days 17-31 (Figure 15B). RF induction was not observed in R704 and remained below the 2-fold 
mark throughout the time course. In contrast to R703, Mx1 induction in R704 was much lower, where a 
7-fold increase was observed on day 24 with a slight increase four days later.  
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Figure 15. Longitudinal analysis of RF and IFNγ induction in intermediate animals. 
 The fold change in the relative expression of each RF, Mx1, and IFNγ in PBMC are plotted (A) R703, (B) 
R704. Each gene is depicted by a different colored bar as indicated in the figure legend; plasma virus 
loads are shown by the black line and the right Y-axis.  Fold change was calculated by dividing the 
relative mRNA level at each time point by the constitutive level observed at baseline. Mx1 was not 
measured on day 31 for both animals. Black solid line indicates the threshold for the observed induction 
to be true. Asterisks next to day numbers indicate days of rectal challenge.  
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4.4.3 ISG time course in the resistant animals 
 A different scenario was observed with the PBMC time courses of the resistant animals. Both R697 and 
R698 displayed a lack of ISG or IFNγ induction, despite six repetitive challenges, until they became 
viremic (Figure 16). Induction levels in both macaques did not pass the 2-fold threshold mark until 10 
days after the 6th challenge (day 45). However, R697 displayed a 4-fold increase in Mx1 levels by day 42, 
the first time point of detectable viremia. Due to lack of available sample, it is unknown if R698 also 
induced Mx1 to similar levels on day 42. Ten days after the 6th challenge (day 45), both animals showed a 
10-14 fold increase in Mx1 which was maintained over time in R697 but not in R698, where Mx1 levels 
were downregulated 25 days after initial viremia (day 67). RF levels were slightly induced, about 2-3 
fold, in R697 on day 67 and 80 but remained below the 2-fold mark thereafter (Figure 16A). 
Interestingly, tetherin was the most highly induced RF in both R697 and R698. On day 100 (58 days after 
viremia) for R697, an 8-fold increase in tetherin expression was observed and was maintained to a lesser 
extent on days 142 and 205. R698 also had a 3-fold increase in tetherin on day 142 (Figure 16B). It is 
interesting to note that despite five challenges, little to no RF induction was observed over time for both 
animals until the 6th challenge that resulted in a systemic infection. Unlike the RFs, IFNγ seemed to be 
slightly more induced over the time course of infection in R697, with a 4-fold induction on day 205 (163 
days after viremia) which corresponded with the log decrease in virus load. Interestingly, persistent Mx1 
induction in R697 corresponded with persistently high virus loads (105-107) whereas transient Mx1 
induction in R698 corresponded with decreasing virus loads (102-105). Earlier time points are shown for 
the resistant animals, as opposed to the other two groups, to better understand how repeated challenges 
affect longitudinal RF levels in animals persistently resistant to infection. In general, these two resistant 
animals did not show notable RF induction over time despite repeated challenges. However Mx1, IFNγ, 
tetherin, and to a lesser extent A3G, were induced in this group, but only after virus appearance in the 
blood. 
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Figure 16. Longitudinal analysis of RF and IFNγ induction in resistant animals. 
The fold change in the relative expression of each RF, Mx1, and IFNγ in PBMC are plotted (A) R697, (B) 
R698. Each gene is depicted by a different colored bar as indicated in the figure legend; plasma virus 
loads are shown by the black line and the right Y-axis.  Fold change was calculated by dividing the 
relative mRNA level at each time point by the constitutive level observed at baseline. Mx1 was not 
measured at all time points. The black solid line indicates the threshold for the observed induction to be 
true. Asterisks next to day numbers indicate days of rectal challenge.  
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 R705 is also considered among the animals in the resistant group; however, it is 
specifically classified as an elite controller. This animal was challenged six times with escalating doses of 
SIV/DeltaB670. No sign of virus was evident until 17 days from the 6th challenge. Levels of virus reached 
104 copies/ml plasma and was maintained at that level for 18 days before virus was no longer detectable 
in the blood for 42 days. After the 7th single high dose challenge (100 fold higher than previous challenge) 
on day 107, R705 became systemically infected once more while maintaining a lower VL in comparison 
to the other animals. R705 blipped a total of three times before it became systemically infected on day 
235. Throughout the time course, no RF induction was observed despite the repeated challenges and the 
single high dose exposure (Figure 17). Induction remained below the 2-fold mark for all examined genes 
with the exception of Mx1 and IFNγ. Interestingly, there was a 4-5 fold induction of Mx1 very early 
during the time course on days 14-28. This induction was observed despite the lack of detectable virus, 
which is opposite to what was observed with the rest of the cohort. The highest level of Mx1 induction 
was observed on day 59 during the first viremic blip but levels remained below the 2-fold mark thereafter. 
It is noteworthy to emphasize that Mx1 was not induced later in the time course despite several viremic 
blips. In contrast to early Mx1 induction, IFNγ was induced later and to a higher extent than the RFs. A 2-
3 fold increase was observed on days 215, 219, 226, and 247. From these time courses, we were able to 
conclude that RF induction occurred after detectable virus in the blood (except for R705), RFs were 
coordinately and transiently induced during initial viremia, Mx1, TRIM5α and tetherin were the most 
highly induced ISGs, repeated challenges had no apparent effect on RF induction, and RF induction did 
not appear to correlate with protection. 
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Figure 17. Longitudinal analysis of RF and IFNγ induction in the elite controller. 
The fold change in the relative expression of each RF, Mx1, and IFNγ in PBMC are plotted for R705. 
Each gene is depicted by a different colored bar as indicated in the figure legend; plasma virus loads are 
shown by the black line and the right Y-axis.  Fold change was calculated by dividing the relative mRNA 
level at each time point by the constitutive level observed at baseline. Mx1 was not measured at all time 
points. The black solid line indicates the threshold for the observed induction to be true. Asterisks next to 
day numbers indicate days of rectal challenge.  
4.5 RELATIONSHIP BETWEEN MAXIMUM RF INDUCTION AND 
SUSCEPTIBILITY TO INFECTION 
 To determine whether intrinsic differences in maximally induced ISG expression could impact 
susceptibility to infection, the maximum expression levels induced post systemic infection was compared 
among the three groups (Figure 18). All animals except R705 were included in this analysis. The 
maximum relative expression achieved for all RFs, Mx1 and IFNγ was fairly similar among the three 
groups, suggesting that the ability to mount a type I interferon response to viral infection was unaffected. 
When fold change in expression was measured at the maximum induction time point relative to basal 
levels, a maximum induction of 2-9 fold was observed in the examined genes (Figure 19B-G). Mx1 
induction at the maximum expression time point was the greatest among the other ISGs with levels 
increasing to 50-fold in the susceptible and resistant groups (Figure 19A). It is important to remember 
that the fold-change in maximum induction for the resistant animals was not as high as the susceptible 
due to the resistant animals’ intrinsically higher basal ISG expression. Overall, these data suggest that the 
maximum induced levels of these genes did not vary among the three groups and further indicated that 
higher RF induction post exposure did not necessarily protect from SIV infection.  
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Figure 18. Maximum ISG and IFNγ expression among the three groups. 
The maximum expression value for each gene throughout the entire PBMC time course was plotted for 
the three groups. (A) Mx1 (B) TRIM5α (C) Tetherin (D) A3G (E) SAMHD1 (F) SCHL11 (G) IFNγ. 
Maximum values were 3-24 days after the 2nd challenge for the susceptible animals, 10-17 days after the 
3rd challenge for the intermediate animals, and 10-170 days after the 6th challenge for the resistant 
animals. Shown is the mean value with SD bars. R705 was not included in the resistant animals. 
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Figure 19. Fold change in maximum ISG and IFNγ expression. 
Maximum PBMC expression values from figure 18 were divided over the relative basal values for each 
gene (A) Mx1 (B) TRIM5α (C) Tetherin (D) A3G (E) SAMHD1 (F) SCHL11 (G) IFNγ. Shown is the 
mean value with SD bars. R705 was not included in the resistant animals. 
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4.6 TISSUE-SPECIFIC ISG EXPRESSION IN THE ELITE CONTROLLER 
 Although the rectum would have been the optimal site to examine the impact of early RF expression on 
susceptibility to infection, the animal’s natural resistance to infection could have been compromised 
during later rectal challenges. However, rectal biopsies were obtained four days prior to and three days 
after the 6th challenge for R705, the elite controller. Relative rectal ISG and IFNγ expression was 
therefore compared to levels in the blood and duodenum to evaluate tissue-specific differences that may 
contribute to resistance.  Similar RF expression was observed in the 3 tissues (Figure 20). More 
importantly, all five RFs exhibited coordinate induction in the three tissues. Even though R705 was 
exposed 6 times before this examined time point, IFNγ levels were extremely low in all three tissues, 
especially at the site of exposure (the rectum), indicating the lack of a mounted adaptive immune 
response. While minor expression variability was observed among the three tissues, these data suggest 
that RFs are coordinately expressed in the blood, gut, and rectum. Collectively, these data suggest that 
ISGs are coordinately expressed in the PBMC, duodenum, and rectum and further reveal the ability of the 
blood to mimic mucosal RF expression. Thus, the blood may serve as a better compartment for examining 
RF behavior in response to pathogen exposure than other lymphoid and mucosal compartments. 
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Figure 20. Tissue-specific ISG and IFNγ expression in the elite controller. 
Relative expression values in the PBMC, duodenum, and rectum are plotted for each gene three days post 
the 6th rectal challenge in R705. 
 
4.7 LONGITUDINAL ISG INDUCTION IN THE DUODENUM 
 In order to understand the significance of the RF induction observed in the blood, it was important to 
correlate longitudinal PBMC RF expression with the longitudinal RF expression seen in the duodenum. 
By evaluating the duodenum, I can specifically understand the interplay of ISG induction in the mucosa 
and its response to rectal exposure. Comparison of the two possible bottlenecks, “windows of 
opportunity,” for systemic infection, as described in the sexual transmission section, may also reveal 
whether one or both barriers contribute to protection. A time course analysis was conducted by examining 
fold-change in expression relative to basal levels of the five RFs, Mx1, and IFNγ in duodenal biopsies 
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from the susceptible animals (Figures 21). The intermediate and resistant animals were not examined due 
to lack of duodenal biopsies at their first viremic time points. Only days 3, 10, and 17 in the duodenum of 
the susceptible animals were examined. While the susceptible animals became viremic by day 14, a 
duodenal biopsy was not available at this time point. Three days after the first challenge, a noticeable 
induction (5-12 fold) in Mx1 was observed in the duodenum of R701 and R702 (Figure 21B,C). Three 
days after virus appearance in the blood (day 17), all three animals displayed pronounced Mx1 and RF 
induction. Specifically, tetherin and TRIM5α were more highly induced (2-7 fold) in all three animals 
compared to the other RFs. This again mimics what was seen in the blood for selective induction of 
TRIM5α and tetherin in these animals. Interestingly, Mx1 induction was the greatest (150 fold) during the 
examined viremic time points in the duodenum of R700 and R701. These induction levels were 3-fold 
greater than Mx1 induction levels at the corresponding time point in the blood of R700 and R701. R702, 
on the other hand, upregulated Mx1 on day 17 to levels that were 30-fold high and these levels closely 
matched that seen in the blood on day 17 (Figure 21C). Taken together, these data suggest that Mx1 
induction as early as day 3 in the susceptible animals can be detected in the duodenum much earlier than 
in the blood, which may suggest earlier and more sensitive virus detection in the duodenum. Additionally, 
Mx1 induction during the first viremic time point was much greater in the duodenum than in the blood 
indicating that both compartments responded differently to the viral challenges but remained relatively 
similar with respect to RF induction over time.   
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Figure 21. Longitudinal analysis of ISG and IFNγ expression in the duodenum. 
The fold change in the relative expression of each gene is plotted for the duodenum of the susceptible 
animals (A) R700, (B) R701 (C) R702. Samples were obtained 4 days prior to the first exposure (basal 
levels). Each gene is depicted by a different colored bar as indicated in the figure legend; plasma virus 
loads are shown by the black line and the right Y-axis.  Fold change was calculated by dividing the 
relative mRNA level at each time point in the duodenum over the basal level observed four days prior to 
the first challenge. The black solid line indicates the threshold for the observed induction to be true. 
Vertical dotted lines are for clarity and separate the RF expression for each day. Asterisks next to day 
numbers indicate days of rectal challenge.  
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4.8 IMPACT OF TRIM5 POLYMORPHISMS ON A HOST’S SUSCEPTIBILITY TO 
INFECTION AND DISEASE PROGRESSION 
  Studies suggest that repetitive low-dose rectal challenges may allow better manifestation of TRIM5α’s 
restrictive ability due to the ability of specific TRIM5 polymorphisms in limiting productive infection 
[134]. Since TRIM5α is the first RF to respond to virus entry, it is plausible that low dose rectal 
challenges may block the few viruses that penetrate the mucosal barrier [134]. Polymorphisms in the 
TRIM5 SPRY domain that encode the binding region of the SIV capsid affect the strength of the 
TRIM5α-capsid interaction and therefore efficient restriction of virus replication [78,79,80]. As 
previously mentioned, three different allelic forms in the 339-341 region of the capsid exist: TRIM5TFP, 
TRIM5Q, and TRIMCYPA.  To determine whether these TRIM5 polymorphisms were associated with the 
observed differences in susceptibility to infection with SIV/DeltaB670 in the cohort, the TRIM5α 
genotype was determined for each animal (Table 9 and Appendix C). 
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 Six of eight macaques expressed the TFP/Q genotype, while R703 and R701 expressed 
the Q/Q and Q/CypA genotype, respectively. The G to T nucleotide substitution in intron 6 was observed 
for two of the TRIM5 clones from R701 indicating presence of the CypA allele (Appendix C, panel B). 
Since the TFP allele is a dominantly restrictive allele, it is reasonable to assume that all macaques (except 
R701) would restrict virus replication and exhibit lower viral set points as previously shown for several 
SIV strains. However, a widespread variability was observed in the cohort’s susceptibility to infection 
despite 6 out of 8 macaques encoding the TFP/Q genotype. When these TRIM5 genotypes were also 
compared to viral set point levels, no correlation was observed to suggest that animals with a restrictive 
allele have lower viral set points and therefore slower disease progression as others have seen [79]. 
Therefore, despite these common alleles that would render the animals resistant to infection with other 
SIV isolates, the full spectrum of susceptibility to infection and disease was observed indicating that 
TRIM5 polymorphisms may not have a restrictive effect on SIV/DeltaB670 replication and host 
susceptibility to infection.  
 
 
Table 9. Relationship between host genetics and susceptibility to infection and disease progression. 
 
Infection Phenotype Animal # 
Genotype 
*Viral Set Point 
TRIM5α Mamu A Mamu B 
Susceptible 
R700 TFP/Q A002a/A004 B017a/B048 2.40E+05 
R701 Q/CYPA A002a/A011 B008/B055 6.00E+05 
R702 TFP/Q A004/A011 B002/B008 1.18E+04 
Intermediate R703 Q/Q A004/A011 B008/B028 3.95E+05 R704 TFP/Q A004/A007 B002/B024a 9.00E+02 
Resistant 
R697 TFP/Q A002a/A051 B017a/B017a 1.30E+06 
R698 TFP/Q A011/A011 B012b/B043a 5.35E+03 
R705 TFP/Q A002a/A003 B043b/B093 1.35E+02 
* RNA copies/ml plasma 
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 As such, MHC Class I genotyping was conducted for the eight animals to determine 
whether the Mamu A and Mamu B haplotypes contributed to the variability in animal disease 
progression. Two dominant alleles Mamu A*01 and Mamu B*017 are known to be associated with 
protection and delayed disease in macaques infected with SIVmac239/251 [135]. These specific alleles 
are critical for the induction of an effective T cell response to lower the viral burden. Genotyping results 
revealed the absence of the Mamu A*01 allele in the cohort but the presence of the Mamu B*017 allele in 
R700 and R697, a susceptible and resistant macaque, respectively. Although R697 was homozygous for 
the B017a allele, this animal had the highest viral set point at 1.3x106 mRNA copies/ml plasma. 
Similarly, R700 carried the Mamu B*017A allele and had a high viral set point of 2.4x105 mRNA 
copies/ml plasma. These results therefore revealed a lack of a relationship between the animals’ Mamu A 
or B genotype and disease progression.  
 Collectively, these data suggest the lack of an association between: 1) TRIM5 
polymorphisms and susceptibility to infection with SIV/DeltaB670; and 2) Mamu A or Mamu B haplotype 
and disease progression. Although a larger rhesus macaque cohort will better solidify these findings, the 
data suggest that each SIV isolate has independently evolved with respect to TRIM5α restriction and that 
SIV/DeltaB670 did not appear to be affected by the MHC class I genotypes and TRIM5 polymorphisms, in 
contrast to what others have seen with other SIV isolates. 
 
4.9 EXAMINATION OF THE TRIM5Α CAPSID BINDING REGION OF 
SIV/DELTAB670 AND DIVERSE SIV AND HIV-1 ISOLATES 
 The negative effect observed on SIV replication from the TRIM5 polymorphisms is only apparent with 
specific SIV strains as a result of variability in the TRIM5α-capsid binding sequence.  Although only 
eight macaques were examined in this study, the apparent independence of infection and disease on the 
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host TRIM5 haplotype in SIV/DeltaB670 infection was puzzling, particularly since SIV/DeltaB670 
originated from one of the first sooty mangabeys found to harbor SIV asymptomatically and since it is 
closely related to another well-described sooty mangabey isolate  (SIVsmE660), whose infection and 
disease is highly influenced by TRIM5 polymorphisms [84,86,109,136,137].  
 To determine whether the apparent lack of association between TRIM5 haplotype and 
control of SIV/DeltaB670 replication was due to sequence differences in the TRIM5α binding region of 
the viral capsid, the inoculum used for the challenges was sequenced. As expected, this site was highly 
conserved and all clones had identical protein sequences. To understand how SIV/DeltaB670 compared to 
other SIV and HIV strains, a portion of the SIV/DeltaB670 capsid sequence was aligned to analogous 
sequences from multiple SIV, HIV-2, and HIV-1 sequences obtained from the Los Alamos National 
Laboratory database and the Kirmaier et al., study [12]. This is a relevant comparison because unlike the 
other RFs, no virally encoded antagonist exists for TRIM5α and thus each virus has escaped TRIM5α 
restriction by specific mutations in the TRIM5α capsid-binding region.  
 Using SIV/DeltaB670 as the reference sequence, a number of amino acid changes were 
noted in comparison to other SIV, HIV-2, and HIV-1 strains (Figure 22). With respect to the SIV strains, 
SIV/DeltaB670 encoded an 89-IPP-91 as opposed to the commonly seen 89-LPA-91 sequence, but still 
retained the R97 residue (Figure 22A). SIVsmE041, SIVsmE660, and SIVsmE543 exhibited similar 
sequences to SIV/DeltaB670 differing only in one amino acid in the 89-91 region. The TRIM5α capsid-
binding sequences of a sooty mangabey (PBJA) and a pig-tail macaque-specific SIV isolate (PT573) were 
identical to the SIV/DeltaB670 capsid sequence. Additionally, an SIV capsid sequence isolated from a 
chimpanzee in Cameroon had identical TRIM5α-binding sites as SIV/DeltaB670. The SIVmacs and 
SIVmne were unique among the other strains in the 89-QQ-91 and S97 residues causing evasion from 
TRIM5α restriction. Strikingly, SIV/DeltaB670, among other prominent SIV strains, displayed a 
TRIM5α-capsid binding sequence that was most similar to African HIV-1 subtype A isolates (Figure 
22B). SIV/DeltaB670 differed from the other HIV-1 subtypes at residues 89 or 90. These results 
emphasized that the TRIM5α capsid-binding region of SIV/DeltaB670 was unique among other well-
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studied SIV strains and the most similar to African HIV-1 subtype A viruses further suggesting similarity 
in response to TRIM5 restriction. Such an association emphasizes the West African origin of this 
SIV/DeltaB670. Despite the presence of capsid residues known to allow TRIM5α restriction, variability in 
resistance to infection with SIV/DeltaB670 does not appear to be driven by the TRIM5 polymorphisms. 
 
 
 
 
Figure 22. SIV/DeltaB670 capsid alignment with SIV and HIV-1 strains. 
A portion of SIV/DeltaB670’s capsid sequence was used as the reference sequence for alignment with 
various (A) SIV and (B) HIV-1 sequences. A sequence from each of the HIV-1 subtypes and its country 
of origin is shown. Red box indicates the TRIM5α binding region in the capsid. Red numbers identify the 
location of these two regions in SIVmac239. All sequences were obtained from the Los Alamos National 
Library Database and the Kirmaier et al. study [12]. Dots indicate residues identical to the reference 
sequence shown in yellow. GenBank accession numbers for each sequence are found in Appendix D. 
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4.10 GENETIC DIVERSITY OF THE VIRAL INOCULUM AND THE STRAINS 
CAUSING SYSTEMIC INFECTION 
To further understand if the variability in infection observed in the cohort was due to selection of specific 
viral strains, envelope sequencing was performed on the inoculum and the viruses selected during early 
infection. The HIV/SIV capsid is a highly conserved gene but can mutate upon host pressure (ex: 
restriction by TRIM5α) [138,139]. In contrast, the Env gene, and the V1 region in particular, is 
hypervariable and known to be the defining region for the presence of specific viral strains in an inoculum 
[112]. Previous studies by our lab revealed that SIV/DeltaB670 is a quasispecies, harboring >10 viral 
variants/clones [112,140]. As such, the V1 region of the Env gene in the inoculum used for this study was 
sequenced to confirm the quasispecies nature of the inoculum. An inoculum that harbors more than one 
viral variant is important to fully recapitulate the genetic diversity of the HIV strains seen in humans. 
Sequence analysis revealed that the virus stock was indeed a quasispecies, harboring five different V1 
clones (Table 10, Appendix E).  
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 To understand whether differences in susceptibility to infection observed in this study 
was influenced by the mucosal selection of a viral variant, viral sequences were analyzed from plasma 
samples during the acute viremic episode of each animal. In general, the susceptible animals selected for 
clones 2 or 3 (Table 10). The intermediate animals selected for clones 2, 3, or 12.  The resistant animal 
R697 selected clones 3 and 12 while R698 selected clone 12 only. The elite controller R705 only selected 
for clone 2 despite the sequencing of 23 viral clones. To further confirm the specific selection seen in 
R705, virus was sequenced from plasma 67 days later. Clone 2 was indeed solely selected for again in 
R705. Together, these data indicate that the viral inoculum was indeed a quasispecies and that each 
animal exhibited variable selection in the viral strain that caused systemic infection. These findings 
indicate that no specific clone seems to be associated with the animal’s susceptibility to infection. Further 
studies are warranted to understand the impact of these clones on the host immune response especially 
with respect to impact of clone 2 on the resistance of R705. 
 
 
Table 10. V1 Env clone frequency in the cohort and challenge stock. 
 
Infection 
Phenotype 
Animal # Clone 
2 
Clone 
3 
Clone 
12 
Clone 
14 
Clone 
17 
Total 
 Virus Stock 17 2 2 1 4 26 
Susceptible 
R700  20    20 
R701  13    13 
R702 13     13 
Intermediate R703 16 2 2   20 R704  10    10 
Resistant 
R697  10 3   13 
R698   16   16 
R705 early 23     23 
R705 late 17     17 
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5.0  DISCUSSION 
RFs have been an intriguing area of lentiviral research for their potent ability to block virus replication. 
Specific adaptation of HIV/SIV to evade the restrictive function of RFs through virally encoded 
antagonists has contributed to their increased attention among other proteins [40]. The power of these RFs 
lies in their ability to be among the first weapons of defense against invading lentiviruses due to their 
constitutive expression in the immune cells affected by HIV/SIV. Additionally, the IFN-inducible nature 
of these RFs makes them an extremely powerful source of innate defense. The constitutive and IFN-
inducible nature of these RFs makes them an integral component of the host intrinsic and innate defense 
system, respectively. The more the impact of these RFs is understood, the closer the field is to hindering 
this deadly virus from irreparable host damage. 
 
 Despite the current knowledge of RF expression in HIV/SIV infection, little is known 
about the potential role of basal expression of A3G, TRIM5α, tetherin, SAMHD1, and schlafen 11 in 
delaying systemic infection and whether their induction may impact the course of an infection. Overall, 
the data I presented has clarified the importance of host RF expression prior to SIV exposure and their 
ability to delay systemic infection. The first major observation of this study was that basal levels of A3G, 
TRIM5α, tetherin, and SAMHD1 in the blood significantly correlated with resistance to infection. 
Animals resistant to intrarectal repetitive low doses of SIV/DeltaB670 had significantly higher basal 
TRIM5α levels (P=0.025, Kruskal-Wallis with Dunn’s multiple comparison test) compared to animals 
susceptible to infection. Second, analysis of RF induction and virus load over an extended time course 
revealed no relationship between RF induction and protection from infection, as seen with high virus 
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loads. Overall, my study has provided important insight into the role of these RFs in the blood, mucosa, 
and lymphoid tissue with the possibility of basal PBMC RF levels being used as a predictor for 
susceptibility to infection.  
 
 Three different forms of susceptibility to infection were observed in the cohort as a result 
of the repetitive low dose rectal challenges: susceptible, intermediately susceptible, and resistant. Most 
peculiar are the three resistant animals, especially the elite controller R705. The resistant animals, R697, 
698, and R705, required 6-7 rectal challenges before systemic infection was detectable, while the rest of 
the cohort became infected after 2 or 3 challenges. Variability in infection has been seen in other studies 
involving repetitive low dose SIV exposure [83,84]. Many factors may explain this variability such as the 
lack of necessary target cells for virus expansion or a strong immune response [141]. Since the cohort 
underwent repetitive low dose rectal challenges, the resistant animals may have experienced a localized 
mucosal infection that was quickly overcome by either innate immune cells such as NK cells or 
macrophages, or the virus was eliminated by a T cell response in the mucosa induced by the early 
challenges. This was previously seen with rhesus macaques protected from SIV/DeltaB670 infection as a 
result of an SIV env-specific MHC-restricted CTL response induced in the lamina propria by a single low 
dose mucosal exposure [25]. 
 
 The variability in susceptibility to infection was hypothesized to be due to higher basal 
RF levels. Examination of the basal mRNA levels of the RFs, Mx1, and IFNγ by RT-PCR revealed higher 
expression in the blood versus the gut. Such differences may rise from variability in the cell type 
population in each compartment. In general, all five RFs are expressed in hematopoietic cells and the 
population of these cells varies in the blood, ILNs, and the duodenum Approximately 40% of the total 
lymphocyte population resides in the lymph nodes whereas only 2% is found in the blood and 6% in the 
lamina propria of the gut [142]. Expression of A3G and SAMHD1 is particularly high in myeloid cells, 
whereas tetherin is constitutively expressed in mature B cells, plasma cells and pDCs [30,52,92,102]. 
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Studies report that SLFN gene expression can also vary during a cell’s response to infection and during 
macrophage and T-cell development [143]. Such observations may therefore account for the differences 
in basal levels seen in the three compartments. Tissue-specific variability may also result from differences 
in basal IFNα expression. Basal type I interferon expression can vary in different cell types and lymphoid 
tissues with higher expression seen in CD4+ T cells than in CD8+ T cells [144,145]. These discrepancies 
can be confirmed in future studies by single cell analysis to allow for a more accurate quantification of RF 
mRNA levels in various immune cell subsets that express these RFs. 
 
 Examination of basal RF expression in the three compartments revealed a positive 
correlation between basal RF levels and resistance to mucosal infection, indicating the potential impact of 
RFs in delaying systemic infection. Animals resistant to infection with SIV/DeltaB670 exhibited 
significantly higher basal levels of TRIM5α and Mx1 in the blood compared to susceptible animals. 
Similar trends were also seen with SAMHD1, tetherin and A3G in the blood. These findings are 
consistent with another study where higher basal huA3G levels in PBMC correlate with a decreased 
susceptibility to in vitro infection with HIV-1 [115]. Similarly, another group propose a positive 
correlation between basal human A3G expression and resistance to disease progression. Jin et al. show 
that highest A3G expression is found in long-term nonprogressors>HIV-uninfected>progressors [117]. 
They further hypothesize that basal A3G mRNA levels in PBMC is a constant that is determined by host 
genetics and individuals more resistant to disease progression will have higher basal A3G levels 
[117,146]. It is intuitive to believe that higher basal RF expression would render an animal more resistant 
to infection; however, I did not expect this trend to be more prominent in the blood versus the lymphoid 
and mucosal compartments, especially since virus predominately replicates in the latter two tissues due to 
higher target cell levels. The observed trend may be more prominent in the blood than in the ILNs or 
duodenum as a result of differences in the cell population as previously stated. Similarly, since the LNs 
and gut experience the greatest virus replication, basal RF levels may have no protective effect in these 
compartments due to saturation by virus that may hinder cellular activities including RF mRNA 
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transcription. In general, higher basal RF levels in the blood may serve to delay systemic infection during 
the second “window of opportunity” when virus is disseminating to lymphoid tissue and establishing a 
reservoir.  
  It is interesting that basal TRIM5α and Mx1 expression exhibited the strongest positive 
correlation with resistance to infection. Closer scrutiny of the data revealed that TRIM5α’s behavior in 
the blood and ILNs of the three groups mimicked the behavior seen for Mx1 expression. This suggests 
that, among the other RFs, TRIM5α may respond in a similar and early fashion as Mx1 after virus 
exposure and IFNα induction. The similar expression profile of Mx1 (a common ISG) and TRIM5α 
confirmed that the differences seen among the groups are not an artifact and are in fact a novel 
observation worthy of attention. These observations may be useful in future macaque studies allowing the 
use of basal TRIM5α levels in the blood as a screening tool to predict host susceptibility to repetitive low 
dose rectal challenges for a more accurate randomization of study groups.  
 
 In contrast to the correlation between basal RF levels and resistance to infection, no 
correlation was observed between basal RF expression in the PBMC/ILNs and resistance to disease 
progression. However, there was a significant negative correlation between basal TRIM5α levels in the 
duodenum and viral set point. In the blood, higher basal TRIM5α expression contributed to resistance to 
infection; and in the duodenum, higher basal TRIM5α expression contributed to a lower viral set point 
and slower disease progression. It is unclear why this effect on disease progression was only observed in 
the duodenum. One possible explanation is since the majority of HIV/SIV replication during chronic 
infection occurs in the gut, any form of protection in the gut (ex: higher basal RF expression) is likely to 
aid the host by limiting virus replication and dissemination. Additionally, since the gut includes a large 
number of HIV/SIV target cells [147], higher basal levels can inhibit further expansion of virus 
replication in the gut to allow for a more potent adaptive immune response to take place. The persistently 
negative correlation observed only in the blood may indicate RF levels in the blood operate as a potent 
barrier for the establishment of infection and disease.  
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 After observing a correlation between basal RF levels and resistance to infection and 
disease, it was important to understand whether early RF induction had an impact on virus replication in 
the mucosa and therefore control of systemic infection. A coordinate but transient induction of the RFs 
and Mx1 was observed in the susceptible and intermediate animals only during viremia. The similarity in 
the expression profile of Mx1 and the RFs, which are also ISGs, further verifies the integrity of my 
results. My findings are consistent with another study observing a transient 2-3 fold induction of A3G in 
rhesus PBMC within 2 weeks of infection that corresponded with the 30 fold induction of Mx1 [121]. 
Transient RF induction may reflect the transient nature of the IFNα response during a viral infection 
[132]. RFs work in a synergistic fashion with type I interferons. Since IFN expression is transient and 
primarily effective during the initial stage of infection, it is understandable that the RFs were induced 
transiently during viremia [27]. Transient expression may also reflect cellular damage to the host cell by 
the incoming virus, which may disable cellular antiviral defense by the upregulation of these RFs through 
type I IFNs.  
 
 Although all five RFs are ISGs, the pattern of induction of Mx1 and the RFs differed in 
the animals. Mx1, TRIM5α, and tetherin were selectively induced in tandem. Selective induction of Mx1 
among the other ISGs, may be due to the nonspecific induction of Mx1 during an infection by IFNβ prior 
to RF induction by IFNα as shown in figure 4. Mx1 induction was particularly high for the susceptible 
and intermediate animals (8-40 fold) while resistant animals only exhibited a 4-16 fold increase. These 
findings are in agreement with another study observing persistently higher Mx1 induction in progressor 
macaques while little to no Mx1 induction was observed in the nonprogressor [132]. Previous studies 
show that Mx mRNA levels are a reliable indicator of ongoing virus replication, where higher Mx levels 
in chronically-infected macaques strongly correlate with increased VL [132]. The persistent Mx1 
induction in R697 and the corresponding high VL may confirm earlier studies that show persistent IFNα 
production causing a heightened level of immune activation and T cell apoptosis thereby facilitating 
further virus replication and disease progression [34].  
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 The transient, selective induction of Mx1 during the early failed challenges in R705 
distinguished this elite controller from the rest of the cohort. The 4-5 fold increase in Mx1 levels confirms 
R705 was exposed to the virus during the first or second challenge but was able to limit productive 
replication because it expressed significantly higher basal Mx1 levels than the susceptible animals. 
Indeed, type I interferon and Mx induction can occur through the presence of viral proteins alone without 
virus replication [132,144]. Since Mx1 was not induced once infection was established in the elite 
controller, this lack of Mx1 induction may indicate protection as others have seen [148]. For example, the 
nonpathogenic AGM model of SIV is known to show a decrease in Mx1 response during the chronic 
stage of infection [132]. Specifically, AGMs and SMs have the unique ability to control immune 
activation by rapidly downregulating acute phase type I IFN during the transition to chronic infection 
[148]. This feature is what differentiates them from the rhesus macaque pathogenic model.  
 
 TRIM5α and tetherin were the most highly induced RFs in the PBMC of the susceptible 
animals during initial viremia. Contrary to my hypothesis, RFs were not induced in the resistant animals, 
despite repeated viral challenges, until they became viremic. These findings are consistent with a previous 
study showing higher A3G, TRIM5α, and tetherin mRNA levels in HIV-1 infected untreated patients 
(UT) than patients on antiretroviral therapy [119]. Variability in the selective induction of these RFs 
during initial viremia in the susceptible animals could reflect differences in T cell activation. This may be 
true since in HIV-1 infected untreated patients, T cell activation positively correlates with TRIM5α and 
tetherin expression [119]. Additionally, selective RF induction may be due to stimulation by cofactors 
other than IFNα [39]. For example, tetherin can be induced through type I interferon-independent 
pathways through TLR 8 in myeloid cells [91]. 
 
 It is known that HIV exposure can trigger A3G induction in PBMC even without signs of 
infection [116]. However, induction was not observed beyond the 2-fold threshold in the resistant 
macaques until they became viremic from the 6th or 7th challenge. More importantly, there was a lack of 
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RF induction in the elite controller which is in agreement with others who have shown no difference in 
A3G, TRIM5α, or tetherin expression in HESN and healthy controllers [119].  One group proposes that 
early PBMC type I IFN responses (example: RFs) do not control virus replication nor result in a 
nonprogressor monkey [132]. This is supportive of our findings because early RF induction in PBMC was 
associated with viremia and not protection.  
 
 A possible explanation for the lack of RF induction in the resistant macaques can be due 
to lack of virus that successfully penetrated the epithelial layer to induce the innate immune response. 
This may be especially true since RF induction only occurred during viremia. Another explanation is 
there may be a difference in RF function before and after infection. Essentially, higher basal RF levels in 
the blood can have a potent effect on resistance to infection by arming the host with necessary defense 
proteins. However, it may be “too late” for RF induction to play a role in the blood after infection if a 
host has lower basal levels to begin with. This may be especially true since at the point of virus detection 
in the blood, virus is establishing lymphoid reservoirs [20]. 
 
 Collectively, these data suggest that RF induction does not correlate with protection, 
especially since susceptible animals showed the greatest RF induction [33]. Despite the 2-7 fold induction 
of the RFs and the 30-50 fold induction of Mx1, virus levels remained high. My observation is in 
agreement with another study observing higher tetherin levels directly associated with VLs and disease 
progression [119]. Further corroborating this hypothesis is the high VL of R697 in addition to the 8-fold 
induction of tetherin during chronic infection. Contrary to other reports where higher PBMC A3G levels 
in HIV-1 exposed seronegative individuals inversely correlated with disease progression, I noticed a lack 
of A3G induction among the three resistant animals to indicate they are protective [115,116]. Similarly, 
no inverse relationship between RF expression and virus load was observed as others have seen with 
rhA3G [121].  
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 The lack of an association between induction and resistance to infection was also 
confirmed by examining the maximum RF levels achieved for each animal. Maximum levels attained for 
the animals in the three groups were highly similar indicating that the overall expression of RFs post-
exposure had no impact on an animal’s resistance to infection. RFs may become passive to repeated 
challenge, reaching a threshold of induction whereby they could no longer control virus replication and 
contribute to protection. Studies in HIV-1 infected humans show that with increasing VL, ISGs involved 
in antiretroviral defense also increase [27]. When antiretroviral therapy is given to these individuals with 
high levels of HIV-1, the ISG profile returned to levels similar to uninfected individuals indicating that 
the lack of ISG induction in macaques, especially in R705, may be causing protection. Since transient 
IFN expression is known to limit the first rounds of replication and since IFNα has a finite time to 
effectively prevent productive HIV replication as previously seen in macrophages, RF induction during 
the first 24-48 hours after exposure may be more informative to study and allow for a better 
understanding for the possible protective effect of these RFs [27,61].   
 
 Since RF induction was not observed after the first 5 exposures in the resistant animals, 
this raised the question of what was causing these animals to remain resistant. One of the common 
parameters for determination of resistance to HIV disease has been analysis of host genetic factors (HLA 
Class I alleles, CCR5 polymorphisms, and chemokine copy numbers) [149]. Many studies have shown an 
animal’s MHC Class I genotype capable of affecting VL and disease progression. Specifically, alleles 
A*01 and B*17 are known to cause protection for SIVmac239/251-infected macaques [135]. I therefore 
determined the MHC Class I Mamu haplotypes of the cohort and found no association between the MHC 
class I Mamu haplotypes and virus loads and disease progression. This supports previous findings from 
our lab. Specifically, the protective Mamu A*01 allele was shown to have no impact on SIV/DeltaB670 
replication [150]. My study, however, has added the lack of an impact for the Mamu B*17 allele as well. 
Therefore, other unknown factors may play a role in the persistently low viremia detected in R705. 
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 Since the rectum and gut are exposed to virus prior to the blood, it was important to 
understand how RF expression varied in these compartments. Studies have shown SIV can be detected in 
the digestive mucosa within four hours of intrarectally-infected rhesus macaques [151]. RF expression 
was therefore examined in the duodenum and rectum of the elite controller and compared to RF 
expression in the blood. I hypothesized that RF expression would vary in the blood versus the mucosa 
with higher expression in the mucosa since that is the primary portal of entry for HIV. Examination of the 
RFs in the three tissues revealed similar expression levels. The slight variability can simply be due to 
immune signaling. After virus enters the mucosa, the innate immune response is triggered. At that time 
the rectum may have low basal levels of these RFs and becomes overwhelmed by the entering virus and 
unable to upregulate RF expression. However, the immune system has been alerted which may allow for 
upregulation of these RFs in the blood before the virus enters the periphery. Only rectal biopsies on day 
38 for R705 were available and while that might have not been an optimal time point, the data suggest 
that future analysis of RF expression changes in the mucosa can be more easily monitored in the blood 
due to similarity in expression among the three tissues.   
 
 The coordinate expression of RFs in the blood in response to infection was further 
verified by longitudinal analysis of RF expression in the duodenum. RF induction was observed in the 
duodenum of animals susceptible to infection, especially during initial viremia. Of particular interest is 
the 5-10 fold induction of Mx1 on day 3 in the duodenum of R701 and R702, which was not observed in 
the blood. This induction confirms exposure in the mucosal compartment allowing a rapid response from 
the innate immune cells in the duodenum than the blood. However, this Mx1 induction did not appear to 
protect the host, as these two animals became systemically infected 11 days later. Therefore, selective 
induction of Mx1 alone is insufficient in protecting a host from subsequent mucosal exposure if they are 
intrinsically more susceptible to infection. While the duodenum and blood appeared to exhibit similar ISG 
expression in the susceptible animals, Mx1 was the exception as seen by earlier induction in the 
duodenum and a stronger induction by day 17. This observation is supported by another group that found 
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higher Mx levels in lymphoid tissues than in the PBMC of acutely infected monkeys [132]. Higher Mx1 
induction in the duodenum can also be due to persistent virus replication since mucosal mononuclear cells 
experience a greater viral burden than PBMC [147].  
 
 Genetic polymorphisms in TRIM5 have also been shown to play a role in the 
susceptibility to infection and disease with some SIV isolates and not others. Previous studies have 
established that macaques with restrictive TRIM5 alleles (TFP or CypA) are more resistant to 
SIVsmE660 and SIVsmE543 infection than macaques expressing the susceptible (Q) allele. These 
polymorphisms inhibit virus replication regardless of the route of exposure but are dependent on the SIV 
strain used. However, I did not identify a relationship between the TRIM5 polymorphisms in the SPRY 
domain and susceptibility to infection with SIV/DeltaB670. This implied other cofactors imparting a role 
on host susceptibility that may or may not work in concert with the TRIM5 polymorphisms. Previous 
studies have established that animals expressing restrictive TRIM5 alleles require more rectal/penile 
exposures to become infected with SIVsmE660 [84,86]. Specifically, animals with the TRIM5TFP/CYPA 
genotype require more than 10 challenges to become systemically infected. However, I observed a 
widespread variability in animal susceptibility to infection, which did not seem to relate with the TRIM5 
polymorphisms as others have seen with SIVsmE660 and SIVsmE543. Therefore, despite the origin 
similarity of SIVsmE660 and SIV/DeltaB670, the latter virus did not appear to be affected by the TRIM5 
polymorphisms as the former virus. 
 
 The primary difference in variable TRIM5 restriction lies in the capsid sequence of the 
TRIM5α binding site. SIV/DeltaB670 appears to have behaved differently from other SIV strains in that it 
was not affected by the TRIM5 polymorphisms, but was susceptible to restriction. By analyzing the 
TRIM5α binding site in the SIV/DeltaB670 capsid, I was able to determine that SIV/DeltaB670 may be 
resistant to TRIM5 polymorphisms due to the genetic sequence of the capsid. The 89-91 and 97 amino 
acid regions in the TRIM5α binding site of SIV/DeltaB670 encoded a unique sequence not seen in any 
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other SIV strain with the exception of the SMM PBJA and PTM PT573 isolates. The similarity of 
SIV/DeltaB670 to the latter two isolates may indicate that all three respond to TRIM5 restriction in a 
similar fashion. Strikingly, the SIV/DeltaB670 TRIM5α binding site was most similar to several African 
HIV-1 subtype A isolates which confirms that SIV/DeltaB670 may have originated from West Africa. 
This similarly may further suggest that SIV/DeltaB670 is a virus more representative of HIV-1 than other 
SIV strains with respect to TRIM5 restriction. Further analysis of how TRIM5 polymorphisms may 
impact rhesus macaque disease progression will be immensely beneficial in creating a more HIV-1 tropic 
rhesus macaque model and perhaps pave the way for effective gene therapy against HIV-1 [152].  
 
 In this report, I recapitulated the intrinsic role of RFs in defending the host from SIV 
infection. As stated earlier, RFs are specifically part of the intrinsic immune system in that they are 
constitutively expressed without aid from the host immune system [44]. RFs may serve as the initial 
trigger for stimulation of innate and adaptive immunity in an infected host. My report further supports this 
definition through the discovery of basal levels of TRIM5α potently delaying susceptibility to infection. 
While the size of the cohort is a limitation in this study, statistically significant data was obtained with 
clear differences among the groups (susceptible, intermediate, and resistant). Additionally, there was a 
notable variability in susceptibility to infection with the cohort that truly allowed me to validate the 
conclusions made.  
 
 Taken together, this study provided several novel observations that have the potential to 
significantly impact the field: 1) higher basal RF levels may serve as a predictor for susceptibility to 
infection; 2) early and late RF induction does not appear to protect from infection but may impact disease 
progression; 3) TRIM5 polymorphisms do not appear to impact SIV/DeltaB670 replication kinetics like 
they do for other SIV isolates; 4) SIV/DeltaB670’s TRIM5α capsid binding site is unique and most 
similar to African HIV-1 isolates and may thus serve as a better strain for HIV macaque studies; and 5) 
blood may serve as a window for understanding RF behavior in the mucosa. 
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5.1 PUBLIC HEALTH IMPLICATIONS 
 Identification of the potential protective impact of basal RF levels on a host’s susceptibility to infection 
and disease progression is a novel observation that may significantly impact the field. My study has 
shown higher basal RF levels can contribute to delayed mucosal infection which can be further translated 
in other macaque and human studies to allow for screening of blood samples for RFs as a predictor of 
susceptibility. The ability of basal mRNA levels of TRIM5α to predict susceptibility to infection and 
disease progression can have a significant impact on the field. These data suggest that future clinical 
studies that immunize macaques with an adjuvant to upregulate RF expression (especially TRIM5α) may 
allow prevention of infection or delayed disease progression. Similarly, perhaps therapeutics or 
microbicides in the form of RF gene therapy can allow a host to eliminate the virus early after exposure. 
Upregulation of basal RF expression in the form of microbicides will be especially beneficial in the 
mucosa (rectum or vaginal tract) to effectively block virus dissemination. The observation that RF 
induction in the blood mimics that seen in the duodenum also has a significant impact on the field by 
allowing scientists to easily assess and obtain macaque blood samples to evaluate the changes seen in the 
gut after mucosal exposure.  
 Thus, in order to fully harness the potency of these RFs in the context of HIV infection in 
humans, scientists must explore different avenues to enhance RF function or block antagonist function. 
Several groups have already experimented with various methodologies to maximize the potency of RFs in 
humans and nonhuman primates. First, small molecular inhibitors of viral antagonists can be designed to 
specifically allow RFs to practice their function unhindered [51]. This has already been performed against 
HIV-1 Vif and results reveal reduced viral infectivity and higher cytidine deamination of the viral genome 
[153]. Therefore, by specifically eliminating these antagonists through the use of drugs or siRNA, RFs 
will be more functional. Second, the inhibitory function of RFs can be coupled with vaccines to maximize 
the antiviral effect by usage of adjuvants to specifically upregulate RF expression [154]. One study 
observed that the TRIM5 haplotype coupled with vaccine-induced immune response may have a potent 
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protective impact on a host [85]. Finally and perhaps most importantly, RFs can be utilized as a form of 
gene therapy. For example, a form of gene therapy using huTRIM5α that carries the P332R mutation 
known to allow for HIV-1 restriction may contribute to a better block of HIV-1 in humans [26]. 
  In essence, identifying the role of these RFs in virus inhibition may identify possible 
mechanisms to optimize their interplay with the innate immune response to further aid in the design of 
drugs/microbicides that could target virus prior to dissemination. By implementing these methods, 
humans may maximize the natural potency of these RFs and enable them to curtail virus replication at the 
onset of transmission.  
 
5.2 FUTURE DIRECTIONS 
 While this work has provided valuable insight into the role of RFs during repetitive, low dose infections, 
more work is warranted to fully understand their cellular function. First, and of high importance, is single 
cell analysis of RF expression in various cell types to determine whether RFs are specifically induced in 
immune cell and whether the cell that is constitutively expressing the RF is the same one responsible for 
induction. By understanding the basal mRNA and protein levels of each RF in hematopoietic cells, 
powerful conclusions can be made regarding the specific immune cells responsible for protection after 
exposure. Second, the observation that resistant animals have significantly higher levels of TRIM5α will 
be further validated by screening rhesus macaque blood samples for basal levels of TRIM5α to predict an 
animal’s susceptibility to infection with repetitive low dose rectal challenges. Third, since RFs are early 
responders to virus invasion, perhaps examining induction within hours from infectious exposure in other 
mucosal and lymphoid tissues including the jejunum and mesenteric lymph nodes would confirm our 
observation that the blood may in fact be a more valid source for understanding host susceptibility to 
infection. Fourth, immunological studies are necessary to understand the nature of the adaptive immune 
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response in all animals, especially in the elite controller. Fifth, siRNA knockdown studies examining the 
individual potency of each RF in infected human and rhesus cells may elucidate the power of a single RF 
or the necessary cooperative interaction among them. Future studies examining the ability of animals 
shown to be resistant to SIV infection in vivo to also resist infection in vitro will further confirm my 
findings [155]. 
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APPENDIX A 
DERIVATION OF SIV CHALLENGE STOCKS USED IN NONHUMAN PRIMATE 
STUDIES 
 
 
        Figure adapted from [156]. 
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APPENDIX B 
LINEARITY AND EFFICIENCY OF THE TAQMAN ASSAYS 
 
 
 
PBMC cDNA was serially diluted and amplified using each Taqman primer/probe set and the 
corresponding Cq (quantification cycle) was plotted at each cDNA concentration. Linear 
regression analysis was performed to evaluate assay linearity (R2) and efficiency (1-10 -1/slope).  
All lines had R2 values >0.99 indicating linearity. Slopes were between -3.3 and -3.6 and 
therefore efficiency was >90%. 
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APPENDIX C 
SEQUENCE ALIGNMENTS OF THE TRIM5Α B30.2/SPRY DOMAIN 
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A portion of the TRIM5α B30.2 domain was PCR amplified to determine the polymorphisms 
present in region 339-341. Four clones were chosen from each animal and sequences were 
aligned (A) R700 (B) R701 (C) R702 (D) R703 (E) R704 (F) R697 (G) R698 (H) R705. Noted 
next to each animal clone number is the polymorphism present. The TFP polymorphism 
corresponding to region 339-341 is found in region 34-36 above and the Q polymorphism 
(characterized by a deletion of residues 338 and 339) is found in residue 34 or 36. The residue 
numbers in the alignments do not correspond with the residue location in the TRIM5 gene. 
Below the TRIM5 sequence alignment for R701 (B) is a portion of the nucleotide region in 
TRIM5 for two clones showing the G to T nucleotide substitution indicating presence of the 
CypA allele. 
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APPENDIX D 
ACCESSION NUMBERS FOR THE SIV AND HIV SEQUENCES  
 
 
All accession numbers were obtained from GenBank and Kirmaier et al. [12]. 
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APPENDIX E 
V1 ENV SEQUENCE ALIGNMENTS OF THE INOCULUM AND THE STRAINS 
SELECTED IN EACH ANIMAL DURING INITIAL VIREMIA 
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A portion of the V1 Env protein sequence is shown. Viral cDNA from animal plasma samples 
during acute viremia were sequenced and aligned using SeqPublish (Los Alamos). Clone 
reference sequences were obtained from GenBank and Amedee et al [112]. Highlighted in 
yellow are the animal numbers and the time point of the isolated cDNA. Parentheses in the far 
right indicate the number of clones sequenced with identical sequences. Dashes indicate residues 
identical to the reference sequence. Dots indicate incomplete sequences. The following are the 
accession numbers for the reference sequences: clone 2: AY118205.1, clone 3: AY118204.1, clone 
12: AY118213.1, clone 14: AY118216.1, clone 17: AY118217.1 
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